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Osteosarcoma is a rare disease, yet it is the most common primary malignancy of bone and 
thus, responsible for a considerable number of deaths. With the introduction of multidrug 
chemotherapy in the 1970s osteosarcoma patient survival rates increased from a low 20% to 
approximately 60-75% if localized disease is present. In contrast, survival rates in case of 
metastatic osteosarcoma remains at a low 20% despite the use of multiagent chemotherapy. 
Modern standard osteosarcoma therapy starts with the histopathological confirmation of the 
disease and continues with neoadjuvant chemotherapy and surgical removal of the tumor 
tissue. Subsequently, adjuvant chemotherapy is initiated. Despite this multimodal approach, 
the absence of significantly improved patient survival rates for approximately four decades 
asks for novel strategies to improve osteosarcoma therapy. The present work deals with 
different approaches of how to potentially improve treatment efficacy, functioning at multiple 
levels.  
First, the limited amount of patient samples requires researchers to use the available primary 
tissue as efficiently as possible. However, most often biopsied, chemotherapy naïve tissue is 
studied. Despite the larger availability of chemotherapy treated tissue, resected tissue is 
hardly studied due to potential influences of therapy on tumor biology. In course of this thesis 
we studied known and putative tumor suppressors in osteosarcoma tissue prior to and after 
chemotherapy. We showed that the use of chemotherapy treated samples is feasible and 
biologically relevant by confirming the prognostic value of known tumor suppressors such as 
p53 or PTEN in osteosarcoma. In addition, we demonstrated via immunohistochemical 
analysis of post-chemotherapy osteosarcoma samples that patient survival and therapy 
outcome is influenced by the presence of cytoplasmic p16 in tumors. In summary, post-
chemotherapy osteosarcoma tissue samples possess research and clinical value and may 
be employed in future studies. Especially with respect to mechanisms of resistance, a better 
understanding of the impact of modern chemotherapy on disease biology is desired. 
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Drugs such as cisplatin (CDDP), doxorubicin (DOX) or methotrexate were successfully used 
against osteosarcoma during the last four decades. However, these highly efficient drugs 
also cause severe side effects and thus, limit the maximum applied dose. One way to 
increase local drug concentration without increasing systemic drug concentration is the 
intraarterial (i.a.) administration of drugs. Despite pharmacokinetic proof of higher local drug 
concentrations after i.a. infusions, earlier clinical trials comparing i.a. administrations of 
CDDP and intravenous (i.v.) administrations yielded conflicting results. To this end, we 
evaluated i.a. versus i.v. administrations of equivalent amounts of CDDP in a controlled, 
experimental study without clinical confounding factors. Using a murine osteosarcoma model 
feasible for multiple i.a. infusions of CDDP, a tumor inhibiting dose of i.a. CDDP was 
identified. Upon comparison, i.a. CDDP was superior in inhibiting primary tumor growth 
compared to i.v. infusions of CDDP. Furthermore, i.a. CDDP reduced the total number of 
lung metastases, potentially owing to the stronger inhibitory effect on the primary tumors. In 
conclusion, i.a. CDDP infusions, not only yielded superior local tumor control, but also 
demonstrated benefit in reducing total numbers of pulmonary metastases.  
The third aim of this work was to improve therapy by targeting metastatic disease, the 
primary cause of death in osteosarcoma. For this purpose, we evaluated an EDA-targeted, 
immunostimulatory TNF-α (F8-TNF), which was shown to be efficacious against 
experimental soft tissue sarcomas. Using a syngeneic murine osteosarcoma model, we 
tested the efficacy of F8-TNF against metastatic osteosarcoma and its dependency on the 
route of administration. Despite the absence of an effect on the primary tumor, a marked 
reduction of metastases was observed, likely due to increased EDA expression of pulmonary 
metastases compared with the primary tumor and an increase in immune cells in the lung 
parenchyma. The route of administration had no major impact on treatment efficacy. Next, 
we developed an amputation model of syngeneic osteosarcoma to evaluate the efficacy of 
F8-TNF, alone and together with DOX. Treatment with F8-TNF, alone or in combination with 
DOX did not significantly inhibit progressed experimental osteosarcomas nor increase 
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immune cells in the lung parenchyma. Moreover, enlarged spleens were observed after the 
treatment with F8-TNF, pointing to an increase in production of immunosuppressive 
leukocytes to counteract the effects of F8-TNF treatment.  
Ultimately, we demonstrated multiple approaches with great translational potential for use in 
the clinics against osteosarcoma. Based on our results, we suggest studying chemotherapy-
treated osteosarcoma samples, especially with respect to studying mechanisms of resistance 
against common chemotherapy. In a second approach, we demonstrated the superior 
efficacy of i.a. CDDP over i.v. CDDP in treating experimental osteosarcomas. We believe 
that i.a. infusions of CDDP have great potential in tumor control, especially in the case of 
easily accessed osteosarcomas of the limbs. Therefore, future preclinical and clinical studies 
should re-evaluate the potential i.a. chemotherapy. At last, we also assessed the potential of 
F8-TNF against metastatic disease. Our results demonstrated efficacy against early 
disseminated disease, however, anti-metastatic efficacy was abolished in large, established 
pulmonary metastases. In summary, future studies against osteosarcoma, might evaluate the 
detailed mechanisms of action of (novel) drugs, and combine them in the best way possible 




Osteosarkome sind sehr seltene Krankheiten, das heißt weniger als 1 Patient pro 2000 
Personen. Nichtsdestotrotz, zählen Osteosarkome zu den häufigsten, primären 
Knochentumoren und sind schuld an einer beträchtlichen Anzahl an Todesfällen. In den 
1970igern begann man mit der chemotherapeutischen Behandlung von 
Osteosarkompatienten und verbesserte deren Fünfjahresüberlebensraten von 20% auf 
ungefähr 60-75% im Falle eines lokalen Osteosarkoms. Trotz Chemotherapie blieben die 
Überlebensraten von Patienten mit metastasierenden Osteosarkomen bei niedrigen 20%. 
Jede Osteosarkomtherapie beginnt heutzutage mit einer Biopsie um das Osteosarkom 
pathologisch zu bestätigen. Danach folgen neodjuvante Chemotherapie, das chirurgische 
Entfernen des Primärtumors sowie der Metastasen und zusätzliche Zyklen adjuvanter 
Chemotherapie. Trotz dieser aggressiven, multimodalen Therapie haben sich die 
Überlebenschancen der Patienten seit ca. vier Jahrzehnten nicht signifikant verändert. 
Aufgrund dieser Tatsache beschäftigen wir uns im Zuge dieser Arbeit mit der präklinischen 
Evaluierung klinisch leicht umsetzbarer Möglichkeiten um bestehende Behandlungs- und 
Prognosemöglichkeiten zu verbessern. 
Da behandeltes Gewebe meist in größeren Mengen vorhanden ist, wollten wir durch 
Immunhistologie zeigen, dass auch die Analyse von behandeltem Gewebe wertvoll ist. Dazu 
verglichen wir unbehandelte Osteosarkomproben mit chemotherapiebehandelten 
Tumorproben. Insbesondere untersuchten wir bekannte und potentielle „Tumor 
Suppressors“. Mit dieser Analyse konnten wir das Wissen über p53 und PTEN, das durch 
Untersuchungen von unbehandelten Gewebeproben bereits bekannt war, anhand von 
behandelten Gewebeproben bestätigen. Zusätzlich identifizierten wir zytoplasmatisches p16 
als einen neuen, prognostischen Biomarker für Osteosarkome. Diese Ergebnisse zeigten, 
dass auch die Analyse von chemotherapeutisch behandelten Gewebeproben möglich ist und 
zum besseren Verständnis der Osteosarkombiologie beitragen kann. Insbesondere bei der 
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Untersuchung von Resistenzmechanismen gegen moderne Chemotherapie kann die 
Analyse von behandeltem Tumorgewebe hilfreich sein. 
Chemotherapeutika wie Cisplatin (CDDP), Doxorubicin (DOX) oder Methotrexate wurden in 
unterschiedlichen Kombinationen mit Erfolg zur Behandlung von Osteosarkomen eingesetzt. 
Allerdings ist der Einsatz jener Medikamente, aufgrund der dosisabhängigen, schweren 
Nebeneffekte, stark limitiert. Intraarterielle (i.a.) Infusionen bieten eine Möglichkeit die lokalen 
Medikamentenkonzentrationen zu erhöhen ohne dabei die maximale, systemische 
Gesamtkonzentration zu überschreiten. Pharmakokinetische Studien zeigten höhere 
intratumorale Wirkstoffkonzentrationen im Vergleich zu intravenösen (i.v.) Infusionen, jedoch 
konnten klinische Studien keine verbesserte Tumorkontrolle in Abhängigkeit des 
Verabreichungsweges demonstrieren. Aufgrund dieser Tatsache verglichen wir die 
Auswirkungen von  i.a. und i.v. CDDP-Infusionen in einem Tiermodell. Mithilfe des 
Tiermodells können Einflüsse, welche in einem klinischen Umfeld nicht vermieden werden 
können, ausgeschlossen werden. Nach der Identifikation einer wirksamen Konzentration von 
i.a. CDDP, verglichen wir die Wirkung gleichwertiger CDDP-Konzentrationen in Abhängigkeit 
ihrer Applikationswege. Das Tumorwachstum wurde am stärksten durch i.a. CDDP 
gehemmt, während i.v. CDDP keine signifikanten Auswirkungen hatte. Nicht nur das 
Wachstum des Primärtumors wurde nach i.a. CDDP gehemmt, auch die totale Anzahl an 
Lungenmetastasen war nach i.a. CDDP am niedrigsten. Diese Ergebnisse bilden eine Basis 
für die (Re-)Evaluierung von i.a. Infusionen von neuen sowie bekannten Medikamente  in 
zukünftigen präklinischen und klinischen Studien.  
Das dritte Ziel dieser Arbeit war es, einen neuen Therapieansatz gegen Lungenmetastasen, 
der häufigsten Todesursache von Osteosarkompatienten, zu finden. Hierfür untersuchten wir 
ein Biologikum namens F8-TNF, ein Antikörperfragment, welches gezielt an EDA-Fibronektin 
bindet und mit TNF-α gekoppelt ist. Frühere Studien konnten bereits die hohe Wirksamkeit 
von F8-TNF gegen subkutane Weichgewebstumore beweisen. Aufgrund der hohen 
Wirksamkeit gegen primäres und erneutes Tumorwachstum testeten wir die Wirkung von F8-
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TNF in einem Tiermodell eines metastasierenden Osteosarkoms. Obwohl keine Wirkung von 
F8-TNF auf das Tumorwachstum festgestellt wurde, kam es zu einer Reduktion der 
Lungenmetastasen, unabhängig vom verwendeten Applikationsweg (i.a. versus i.v.). Sehr 
wahrscheinlich ist dies auf die erhöhte Expression von EDA in den Lungenmetastasen und 
eine Zunahme an Immunzellen im Lungenparenchym von behandelten Tieren 
zurückzuführen. Als nächstes wurde die Wirkung von F8-TNF auf natürlich entwickelte, weit 
fortgeschrittene Lungenmetastasen untersucht. Selbst in Kombination mit DOX konnten 
diesmal keine signifikante metastasenhemmende Wirkung erzielt werden. In 
Übereinstimmung mit der ersten Studie konnte diesmal auch keine erhöhte Anzahl an CD4+ 
und CD8+ Immunzellen im Lungenparenchym identifiziert werden. Allerdings wurde nach 
einer Behandlung mit F8-TNF eine Vergrösserung der Milz entdeckt. Diese Beobachtung 
lässt auf eine Reaktion der Metastasen schließen, welche eine Stimulierung der Milz zur 
Folge hat und möglicherweise zu einer Immunhemmung führt, die das Tumorwachstum 
begünstigt.  
Abschließend kann man sagen, dass die Untersuchung von chemotherapeutisch 
behandelten Gewebeproben biologischen als auch klinischen Wert hat. Speziell zur 
Untersuchung von Resistenzmechanismen herkömmlicher Therapien ist dies ein 
vielversprechender Ansatz. Weiters konnten wir eine verbesserte Tumorkontrolle 
demonstrieren, indem wir CDDP i.a. anstatt i.v. verabreichten. Insbesondere für 
Osteosarkome, welche an leicht zugänglichen Körperteilen auftreten, bieten i.a. 
Verabreichungen zusätzliche Behandlungsmöglichkeiten. Zukünftige präklinische und 
klinische Studien sollten das volle Potential von i.a. Verabreichungen untersuchen. Zuletzt 
untersuchten wir noch die Wirkung F8-TNF auf Lungenmetastasen. Unser präklinisches 
Tiermodell zeigte, dass Immuntherapie prinzipiell gegen metastasierende Osteosarkome 
verwendet werden kann, allerdings gilt es die stark immunhemmende Wirkung von 
Lungenmetastasen zu überwinden. Diese und ähnliche Mechanismen sollten in Zukunft 
durch die Verwendung von präklinischen, realitätsnahen Tiermodellen studiert werden um 
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TACE ................................................................................................... TNF-α converting enzyme 
Tc ............................................................................................................................. Techneticum 
TGF-β .............................................................................................. transforming growth factor β 
TLR4 ................................................................................................................. toll like receptor 4 
TMA ................................................................................................................... tissue microarray 





5.1 Epidemiology of osteosarcoma 
Osteosarcoma is the most frequently occurring primary malignancy of bone. Every year, 
approximately 3 new cases are diagnosed per 1 000 000 persons of a general population (1, 
2). With respect to osteosarcoma incidence as a first cancer, a first peak is observed during 
adolescence (9-25 years; incidence of about 8 cases per 1 000 000 per year) and a steady 
increase with age in the elderly (> 60 years; about 4-5 cases per 1 000 000 persons per 
year) (1). Despite being a rare cancer, osteosarcoma is the most common malignancy of 
bone and thus, responsible for a considerable number of deaths. Especially in pediatric 
patients, bone tumors rank among the five deadliest cancers with a mortality of 
approximately 5 per 1 000 000 (3). Current 5-year overall survival rates are at approximately 
60% dependent on the study, in case of localized disease (4).  Nevertheless, 5-year overall 
survival rates have not changed since the introduction of multidrug chemotherapy in the 
1980s and remained constant for more than three decades.  If metastatic disease is present, 
5-year overall survival rates are still at a low 30%, similar to before the introduction of 
multidrug chemotherapy (4). 
Multiple risk factors are associated with the development of osteosarcoma. Throughout 
different age groups, male sex is associated with a higher risk (56%) for osteosarcoma as 
well as possessing a taller stature (1, 5). Another risk factor for developing osteosarcoma is 
Paget’s disease- a disease linked to a loss of stable bone structure due to remodeling (6). 
Approximately 1% of people with Paget’s disease will eventually develop osteosarcoma (7). 
Besides growth-related bone remodeling, genetic factors- especially loss of tumor 
suppressor genes, and therapeutic radiation are also known to increase the risk for 





5.1.1 Classification of osteosarcomas 
A hallmark, common to all osteosarcomas, is the production of tumor-osteoid (“immature 
bone”) by the malignant tumor stroma (9), nevertheless, osteosarcomas can be subdivided 
into several classes according to their histological appearance and their anatomical site of 
origin (Table 1). Conventional osteosarcomas, the most common form of osteosarcoma 
(about 75% of diagnosed osteosarcomas), arise from the intramedullary cavity of the bone 
and are divided into seven subgroups. Osteoblastic (65%), chondroblastic (10%) and 
fibroblastic (9%) osteosarcomas are generally the most frequently observed forms of 
conventional osteosarcomas and named according to the composition of the predominant 
intratumoral matrix (10).  
Table 1. Subtypes of osteosarcoma. Adapted from reference (11) 





Other primary  
osteosarcomas 
Osteoblastic Parosteal Low-grade (central) 
Chondroblastic Dedifferentiated parosteal Osteoblastoma-like 
Fibroblastic Periosteal Multicentric 
Epithelioid High-grade surface Osteosarcoma of the gnathic bones 
Giant-cell rich  
 
Small cell  
 
Telangiectatic 
Intracortical Post-irradiation  
Disease associated (e.g. Paget’s 
disease, fibrous dysplasia) 
 
5.2 Clinical characteristics and diagnostics 
Before clinical diagnosis, osteosarcomas are usually characterized through symptoms such 
as local pain and swelling, often even for months, until a physician is visited, usually after the 
occurrence of trauma or pathological fractures (12). In suspicion of an osteosarcoma, 
evaluation of the full patient history, physical examination and plain radiography is performed 
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(13). Radiography aids in determining the osseous alterations due to the progression of an 
osteosarcoma and either an osteoblastic or osteolytic or a mixed phenotype can be 
observed. Formation of interspersed calcified islands can also be observed in areas of soft 
tissue. Commonly observed in radiographs is the so called Codman triangle which is marked 
by a triangular ossification of the periosteum in the border region of tumor and healthy tissue.  
Subsequent to the evaluation of the locally affected region, magnetic resonance imaging 
(MRI) can be performed to detect malignant changes in the adjacent soft tissue and to scan 
for potential “skip lesions” (14). In order to systemically detect areas of active bone turnover, 
such as bone metastases, bone scintigraphy (BS) with 99mTc-labelled diphosphonate is 
commonly performed (15). Compared to plain radiography, BS is able to detect bone 
metastases up to 18 months earlier, as biochemical changes occur prior to morphological 
changes (16). Recent developments in imaging technology support the use of positron 
emission tomography (PET) scans with e.g. 18F-FDG as a tracer in order to detect sites of 
active bone turnover, such as those present in osteosarcomas or bone metastases, rather 
than planar BS (17, 18). Especially in combination with computed tomography (CT) scans, 
PET/CT shows superior accuracy and sensitivity compared to BS in detecting bone 
metastases (17). Furthermore, CT scans of the lung are nowadays standard in order to 
detect potential lung metastases if those are suspected (19). Ultimately, a histopathological 
analysis via tru-cut-biopsies (or rarely open biopsies) is always performed in order to verify 
the diagnosis of an osteosarcoma through classifying the genetic make-up, the histological 
subtype, the produced osteoid or matrix as well as the proliferation of tumor cells (13, 20). An 





Figure 1. Overview of clinical imaging modalities used in osteosarcoma. (A) Plain radiograph of a femoral 
osteosarcoma of a 43-year-old female patient. White arrows depict osteoblastic lesions. (B) T2-weighted 
MR image showing an axial osteosarcoma metastasis compromising the spinal canal of a 20-year-old 
man. The arrow points at the tumor extending from the vertebra. (C) Whole body bone scintigraphy 
showing regions of activity in the left distal femur (arrow) of a 14-year-old female patient. (D) PET-CT scan 
of the same patient shown in (C). Arrow points at the primary osteosarcoma in the left femur. A bone 
metastasis is depicted in the epiphysis of the right femur, not detected by BS. The magnified image 
illustrates the overlay of the CT scan (white bones) and the PET-signal (colored area) shown as a 
horizontal section through the right knee. (E) CT scan of the lung of a 15-year-old girl, showing a 
pulmonary metastasis (white arrow). Bones and areas containing mineralized matrix are shown in white. 
(F) The same pulmonary metastasis as depicted in (E) is confirmed by histology (dotted region). The 
central osteoid matrix appears in blue and is surrounded by proliferating osteosarcoma cells. 
After confirmation of the osteosarcoma, grading is performed. Most often the Enneking 
system which combines histological grades (low grade: stage I; high grade: stage II; and 
metastatic: grade III) and anatomical spread (within well-defined compartments: A; extending 
beyond surgical compartments: B) is used (24). In the US, the American Joint Committee on 
Cancer (AJCC) Staging System further distinguishes between tumor size, regional lymph 
node metastases and distant metastases(25).  
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5.2.1 Clinical markers 
Upon diagnosis of osteosarcoma, a risk assessment based on known parameters 
(“markers”) is performed to estimate patient survival. Standard chemotherapy consisting of 
highly cytotoxic drugs such as cisplatin (CDDP), doxorubicin (DOX) and methotrexate can 
induce severe side effects. Thus, it would be of great value to stratify patients before 
administering potentially ineffective but toxic chemotherapy. To this end, identifying the most 
important clinical markers is crucial. 
The strongest single prognostic marker in osteosarcoma is the presence of metastases. If 
metastatic disease is present, five-year survival rates are at a low 16-29% (19, 26, 27). Not 
only presence of metastasis, also increasing numbers of detected metastases imply a worse 
prognosis (27, 28). Despite resection of macroscopic metastases, the disease has already 
spread microscopically and will, in most cases, progress later on (29). Apart from the 
presence of metastases, response to neoadjuvant chemotherapy is another strong 
prognostic factor. The histologic response is determined on the resected specimen and 
divided into good (>90% tumor necrosis) and poor responders (<90% tumor necrosis; a 
detailed classification of responders is found in Table 1). In general, good responders 
achieve up to two times better survival rates compared to patients with a poor histologic 
response (10, 19, 30). Furthermore, patient age, location of the tumor (axial versus limb), 
tumor size, anatomical location of the tumor (e.g. proximal versus distal) and the success of 
surgery also have prognostic value (31, 32). Besides poor histologic response, suboptimal 
chemotherapy (e.g. deviations from the standard protocol) is a chemotherapy-related factor 
for poor outcome (33). Surprisingly, other chemotherapy-related factors such as mild 
toxicities or infections are prognostic markers for improved survival of osteosarcoma patients 
(34-36). High dose chemotherapy is often associated with lymphopenia, leading to the 
attenuation of the immune system. However, the fast recovery of lymphocyte numbers is 




5.3 Biology of osteosarcoma  
Osteosarcoma research suggests a close link between osteosarcoma development and 
processes involving bone growth and bone remodeling such as those taking place during 
puberty or bone-associated diseases. Consequently, most osteosarcomas (75%)  arise in the 
metaphysis of the fastest growing long bones (humerus and tibia) of adolescents and young 
adults (8). As represented by the various manifestations of osteosarcoma (sub classifications 
are shown in Table 1), the actual cell of origin in osteosarcoma is still under debate (38). It 
was first believed that an omnipotent transformed mesenchymal stem cell (MSC) is causative 
for osteosarcomas, however, increasing experimental evidence supports the hypothesis that 
the cell of origin is derived from a pool of MSCs that underwent at least some degree of 
osteogenic-commitment (39).  
However, until now no definitive proof for a specific unique cell of origin for 
osteosarcomagenesis has been identified. Eventually both models are valid to a certain 
degree, explaining the high diversity of osteosarcoma subtypes. Adding to the degree of 
complexity, another recent study also demonstrated a role of the tumor microenvironment in 
defining the ultimate outcome (i.e. osteoid-depositing versus osteoid-negative sarcomas/ 
cancers) of proliferating cells along the mesenchymal-osteogenic lineage after losing 
important tumor suppressors (40). In the end, different cells of origin under the influence of 
microenvironmental cues might ultimately induce osteosarcoma formation (38), yet at a 
different incidence (e.g. MSCs form osteosarcomas at lower frequencies compared to 
osteogenic progenitors) or with different genotypes (e.g. MSCs can form osteosarcomas 
after loss of a higher variety of tumor suppressors than osteogenic progenitors). This gap in 
understanding the origin of osteosarcoma renders osteosarcoma research more difficult (for 
instance in next generation sequencing (NGS) of tumor samples, where the lack of a proper 
control tissue hampers comparative analyses(41)). 
In contrast to the uncertainty about the true origin of osteosarcoma, it is becoming accepted 
that osteosarcoma progression is supported by the action of osteoclasts causing a “vicious 
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cycle” of pathological bone remodeling (see Fig.1; adapted from (42), a concept which was 
already deposited in the context of other cancers e.g. prostate or breast cancer (43)). 
Subsequent to stimulation of mono-nucleated pre-osteoclasts by osteoblasts, activated T 
lymphocytes or osteosarcoma cells via RANK/ RANKL interactions, multinucleated (i.e. 
mature) osteoclasts form and start to resorb the bone matrix. This resorption process 
degrades the inorganic matrix and releases growth factors, among which insulin growth 
factors (IGF) and transforming growth factor-β (TGF-β) are most abundantly present (44, 45). 
In turn, the available growth factors and cytokines lead to a microenvironment that causes 
proliferation of osteosarcomas, which in turn propagate destruction of the host bone, allowing 
the tumor to grow and spread beyond its cortical boundaries (46).  
 
 




5.3.1 Genomic heterogeneity 
Although the clinical course of osteosarcomas is remarkably consistent, the pathological 
appearance as well as the underlying genetic make-up is highly diverse. Despite multiple 
studies analyzing chromosomal abnormalities (47), copy number variations (48), exomes 
(49)or even whole genomes (50, 51), no consistent pattern besides an early or late loss of 
TP53 was detected (52).  In contrast to Ewing’s sarcoma, another class of bone cancers, no 
recurrent chromosomal translocation (such as EWS/Fli1 in the case of Ewing’s Sarcoma) has 
been associated with initiating osteosarcoma development yet (53). Rather a pronounced 
genomic heterogeneity between osteosarcoma samples and, compared to other cancers, a 
high aneuploidy level is observed in studies of osteosarcomas (41). Using non-sequencing 
methods, copy number alterations of osteosarcoma samples were studied and increased 
aneuploidy with a seemingly non-random distribution of specific chromosomal gains and 
losses was detected. These generally high levels of genomic instability were shown to be 
associated with an expression signature of genes involved in cell cycle and replication (54).  
Another phenomenon contributing to high genomic heterogeneity in osteosarcoma is termed 
chromothripsis. Chromothripsis is the process by which massive chromosomal 
rearrangements occur during a single cellular catastrophic event which statistically cannot be 
the consequence of the sequential accumulation of genomic alterations. Interestingly, 
chromothripsis was found to be especially frequent among osteosarcomas (33% of studied 
samples) and other bone cancers (55). These extensive chromosomal changes might further 
contribute to the genomic heterogeneity of this disease entity (41). A third frequently 
observed chromosomal event called kataegis- localized hypermutated regions, was found in 
over 50% of osteosarcoma samples (50). However, regions of kataegis were not associated 
with the most commonly mutated genes. Structural chromosomal variations rather than 
single nucleotide variants were associated with major dysregulated genes in osteosarcoma. 
Until now, the cause of these chromosome-changing events is not fully understood and 
mostly explained by statistical means, not yet by experimental proves. In conclusion, 
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osteosarcoma genomes are strongly heterogeneous due to genetic instability caused by 
multiple chromosomal lesions.   
5.3.2 Molecular markers 
In recent years, due to the trend of personalized medicine, molecular markers in cancer 
diagnosis achieved more and more interest in comparison with clinical markers. The current 
view, that every cancer is different, asks for a per-patient treatment defined by the unique 
genome/ molecular expression pattern of the individual tumors. Until recently, techniques 
such as PCR, comparative genomic hybridization, FISH, karyotyping or 
immunohistochemical techniques were mostly used to study these molecular markers in 
primary tumor tissue until NGS techniques became available and allowed for massively 
parallel analysis of genomic, transcriptomic or epigenomic data. On a genome level, already 
non-NGS studies revealed a correlation between genomic instability of osteosarcoma 
samples and metastasis-free survival of patients (54, 56) or the histological subtype of the 
tumor (57). 
When looking at individual genes, conventional osteosarcomas are marked by a loss of 
heterozygosity (LOH) of RB1 or mutations of RB1 and either type of alteration was found in 
more than 60% of tumors (58). Furthermore, deactivation or loss of TP53 is central in the 
development of osteosarcoma and thus, alterations are observed in approximately 50% of 
osteosarcoma samples (59).  Similarly, loss of CDKN2A due to small deletions or copy 
number losses of PTEN, other major tumor suppressors, are detected in approximately one 
third of osteosarcomas (60, 61). 
Besides loss of functions of these major tumor suppressors, simultaneous amplifications of 
several oncogenes or tumor promoting genes can be found in osteosarcoma samples. 
Among these alterations are amplifications of commonly known tumor drivers such as CDK4 
(a cell cycle promoting kinase)(56) or mdm2 (an inhibitor of p53)(62). Another common tumor 
driver is VEGFA, an angiogenic growth factor required for solid cancers to induce 
angiogenesis, which is also associated with the progression of osteosarcoma (63).  
22 
 
Other known tumor drivers such as c-myc or c-fos are found to be strongly expressed in 
osteosarcomas (64, 65). Of these, expression of the osteoclastogenic transcription factor c-
fos via induction of FGFR1 is considered to play an important role in the lung metastatic 
propensity of osteosarcomas (66). Especially IGF signaling plays an important role in 
osteosarcoma biology (67), by stimulating the formation of bone metastases (68), as well as 
increasing the formation of bone-resorbing osteoclast-like cells (69). In contrast to these 
common tumor drivers, overexpression of RUNX2 seems to be almost exclusively associated 
with the development of bone cancers or bone metastasis, apart from induction of 
lymphomas (70). This observation seems to confirm the critical role of the transcription factor 
RUNX2 in osteoblast differentiation and cell cycle regulation in osteosarcoma development.  
Apart from the above described tumor drivers, metastasis associated genes have clinical 
value and are closely associated with patient survival. Among the most prominent metastasis 
associated genes in osteosarcoma is ezrin, a cytoskeletal linker protein (71). Upon 
phosphorylation, ezrin converts to an active conformation and moves to the cellular 
membrane where it helps stabilizing F-actin (72). Likewise, CXCR4, a chemokine receptor, 
was proposed to have important pro-metastatic functions in osteosarcoma (73, 74). 
Nowadays, serological markers which can be measured using liquid biopsies (e.g. blood 
samples) are intensively studied due to their minimally-invasive quality. In osteosarcoma 
diagnosis, two molecular markers have often been shown to be significantly linked to poor 
survival, namely, high serum levels of alkaline phosphates (10) and increased levels of 
lactate dehydrogenase (32). In contrast to these two (phenotypical) protein markers, 
microRNAs (miRs) have showed great potential as liquid biopsies due to their circulatory 
availability and their regulatory influence on tumor progression at many stages. A recent 
analysis of patient survival-related miRs in osteosarcoma detected a subset of miRs that 
regulate prominent pathways involved in osteosarcomagenesis such as IGF, PTEN/ Akt/ 
mTOR, MAPK and PDGFR/ RAF/ MEK/ ERK (75). More recent studies involving NGS-
techniques, showed that genes involved in osteosarcoma progression are regulated by 
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expression or suppression of certain miRs and thus, miRs are also considered as potential 
therapeutic targets besides their diagnostic value (76). 
Finally, NGS studies contributed to the understanding of disease development and specific 
osteosarcoma treatment. First, NGS studies employing animal models and/or patient 
samples confirmed the contribution of many growth factor signaling pathways and their 
downstream kinases (e.g. PI3K-AKT-mTOR and ERK-MAPK  (51, 77))  to osteosarcoma 
progression as well as the importance of mutations in TP53 and RB1 for osteosarcoma 
progression (50). Second, NGS studies discovered novel important driver genes in 
osteosarcoma progression. For instance, axon-guidance related genes such as SEMA4D 
and SEMA6D were identified as playing a tumor-promoting role in human osteosarcoma 
(77). Furthermore, ATRX (involved in telomere maintenance) and DLG2 (implicated in 
polarity during cell division and cancer cell invasion) were found to be frequently mutated in 
human osteosarcoma samples (50). 
In conclusion, earlier studies investigating proteomic and genomic markers of osteosarcoma 
progression were confirmed by more recent NGS-studies, laying the foundation for the major 
characteristics of osteosarcoma. Future studies will refine the knowledge about 
osteosarcoma by deciphering entire genomes and molecular expression patterns associated 
with specific tumor cells/ stages/ subtypes of osteosarcoma and if possible, individually for 
each patient. 
5.3.3 Metastasis 
As tumors grow and evolve, all malignant tumors will develop metastasis at early or late 
stages. Basically, metastasis describes a process where cells, after being shed from the 
primary tumor, leave the tumor bed and spread throughout the body, most often via the 




Figure 3. Steps of the metastatic cascade. After achieving unlimited proliferative capacity, cells of the primary 
tumor (1) leave the tumor bed and (2) intravasate into the circulatory system. After (3) surviving in the circulation 
cells need to be (4) arrested/ stop at a distant site. Subsequently halted tumor cells (5) extravasate through the 
endothelium and (6) initiate survival programs adapted to a new microenvironment. Successful completion of the 
above steps, results in (7) successful colonization of a distant organ (78). 
Currently, different models of how metastasis exactly occurs are discussed (78). Metastasis 
itself is a very inefficient process, with only about 0.02% of intravenously (i.v.) injected cells 
being able to form growing lung metastases (ignoring the percentage of cells capable of 
leaving the tumor bed) (79). This inefficiency, selects for circulating tumor cells (CTCs) and 
metastases that possess very specific genetic profiles (80). A process called “self-seeding”, 
where CTCs return to the primary tumor bed, to promote tumor progression (81). In 
summary, CTCs (and metastases) experience a sequence of selective processes and 
acquire a different genetic make-up compared to the primary tumor. Hence, systemic 
disease responds differently to the treatment regimens, by evaluating the therapy impact on 
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solely primary tumors in preclinical models. Consequently, the need for the use of 
sophisticated metastatic models in preclinical research to address the specific make-up of 
metastases is required.  
5.3.3.1 Osteosarcoma metastasis 
Not only for cancer in general, also in osteosarcoma metastases are the leading cause of 
osteosarcoma-related death. At presentation, assessment of potentially metastatic disease is 
of outermost importance because presence of metastasis is associated with the worst 
survival prognosis in osteosarcoma (1). Already at diagnosis, between 20 and 25% of the 
patients have detectable metastases (82). Despite surgical removal of the tumor, 
approximately 80% of patients with diagnosed “localized disease” will develop macroscopic 
metastatic disease after surgery (12). Therefore, an equal amount of patients is assumed to 
have non-detectable microscopic metastases at time of diagnosis (29). Most frequently, 
osteosarcoma cells colonize the lungs of patients (74% of metastasized cases) and less 
frequently the bones of patients (10% of metastasized cases) (83). In osteosarcoma, 
metastasis occurs via haematogenous spread rather than lymphatic spread (84). These 
circulating tumor cells (CTCs) have a strong prognostic value in other cancers such as breast 
cancer (85) or Ewing’s sarcoma (86), where overexpression of certain proteins or typical 
translocations are considered as a defining feature of these cancers and thus, can be used 
to identify tumor cells in patient blood. In contrast, defining markers for osteosarcomas are 
missing until now. Nevertheless, a trial in osteosarcoma patients used type I collagen mRNA 
as a marker for circulating osteosarcoma cells and demonstrated a clinical link between 
CTCs and detectable osteosarcoma metastases (87). In addition, animal studies highlighted 
the importance of CTCs and self-seeding for the progression of experimental osteosarcomas 
(88). Besides CTCs and metastases, recurrences are also prognostic factors for poor 
survival and indicators for osteosarcoma spread beyond the primary tumor bed. Local 
recurrences occur in approximately 8-16% of patients and triple the mortality risk, similar to 
development of metastases (83, 89). 
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With respect to the molecular biology of osteosarcoma-specific metastasis, less is known 
compared to carcinoma metastasis because osteosarcomas are rare.  Therefore, murine and 
other animal models mostly contributed to the understanding of mechanisms of 
osteosarcoma metastasis (84). Osteosarcoma metastases often show large genetic variation 
compared to their primary tumors, imposing a limitation to treatments that were developed to 
be effective against primary tumors (90). However, sarcoma cells (including osteosarcoma) 
do not need to undergo epidermal-to-mesenchymal transition (EMT) due to their 
mesenchymal origin. Like many cancers, a common requirement for metastasis in sarcoma 
is the resistance towards anoikis- cell death upon losing contact with the microenvironment 
(91). Anoikis in sarcomas is overcome by forming homotypic (with other tumor cells) or 
heterotypic (with platelets or immune cells) cell-cell contacts or overexpressing proteins such 
as transforming growth factor β (TGF-β) (91). After extravasation, osteosarcoma cells have 
to avoid the immune system while passing through the blood stream. This is partially enabled 
through formation of platelet-tumor cell aggregates which disguise the tumor cells and 
promote arrest of the cells in lung capillaries (in osteosarcoma usually the first organ with 
small capillaries after leaving the primary tumor bed) (84). Apart from these anatomical 
restraints, molecular interactions between the primary tumor (e.g. an osteosarcoma) and the 
target organ (e.g. the lung) were already proposed to play a role in seeding distal organs in 
the 19th century (92). The molecules priming the future metastatic site are distributed via the 
blood stream. For instance, a recent study demonstrated a major role of exosomal α6β4 and 
α6β1 integrins to prime lung tissue for future metastasis in breast cancer (93).  Similar to 
secretion of integrin containing exosomes, secretion of free and exosomal urokinase 
plasminogen activator (uPA) by osteosarcoma cells may contribute to increasing 
osteosarcoma metastasis via degradation of extracellular matrix as well as increasing 
migratory abilities of OS cells (94). 
Recent data highlighted the importance of various stromal cells in priming tumor cells for the 
metastatic process (68). In most cancers, stromal cells such as tumor associated 
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macrophages (TAMs) are considered to have a metastasis-supporting role (95), whereas in 
osteosarcoma TAMS were found to be associated with lower numbers of metastases and a 
good survival prognosis if present at high numbers (96). The direct osteosarcoma inhibitory 
effects of TAMs are partially achieved after macrophage stimulation with IFN-γ and the 
secretion of soluble factors, while the precise inhibitory mechanisms are still unknown (97). 
In contrast to osteosarcoma-suppressing TAMs, other (yet undefined) stromal cells can also 
increase the propensity of osteosarcoma cells to metastasize. Angiopoietin-like protein 2 
signaling was shown to be highly important for enhancing osteosarcoma lung metastasis 
(98). After demethylation of the promoter via the tumor microenvironment, full length 
angiopoietin-like protein 2 was expressed in osteosarcoma cells and induced the expression 
of matrix metalloproteinases (MMPs) that supported intravasation and thus, metastasis of the 
tumor cells. Although no correlation was found between expression of MMP-9 and 
metastasis, a metastasis-supporting role of secreted MMPs may exist, possibly via 
increasing the permeability of the lung endothelial layer, through secretion of systemic MMP-
9 (99).  
5.4 Current therapy against osteosarcoma 
Nowadays, curative treatment of osteosarcoma comprises surgical removal of the primary 
tumor and chemotherapy using highly cytotoxic drugs. Modern chemotherapy backbones 
consist of doxorubicin (DOX, also known under the trade name Adriamycin) and cisplatin 
(CDDP) together with or without methotrexate (100). This chemotherapy backbone 
(methotrexate, Adriamycin, cisplatin; MAP) was fine-tuned during the last three decades and 
increased five-year survival rates to approximately 60-70% (1). In some occasions, 
ifosfamide or etoposide are added, yet without showing additional benefits over effective 
MAP-combinations (101-103). Despite the controversy in the use of neoadjuvant 
chemotherapy, it has been shown to have considerable prognostic value (good response 
versus poor response) and has therefore replaced solely adjuvant chemotherapy (104). In 
German-speaking countries, the Salzer-Kuntschik scheme (Table 2) is commonly used to 
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categorize the histologic response of osteosarcomas in order to evaluate success of 
neoadjuvant chemotherapy (105). In addition to the prognostic value of histologic response, 
neoadjuvant chemotherapy reduces tumor volumes prior to surgical resection and thus, 
facilitates  limb sparing procedures rather than amputation to remove the primary tumor 
(106). The probability to perform limb salvage, however, is higher after a good histologic 
response was achieved in order to fully remove the tumor while minimizing the risk of local 
recurrences (107, 108).  








Individual viable tumor cells or clusters  of cells(< 0.5 
cm) 
Grade 3 < 10% vital tumor 
Grade 4 10-50% vital tumor 
Poor 
response 
Grade 5 > 50% vital tumor 
Grade 6 No effect of chemotherapy 
 
5.4.1 EURAMOS 
In order to keep improving therapy for osteosarcoma, larger clinical trials with sufficient 
statistical power are necessary to compare novel treatments to the current state of the art. 
However, osteosarcoma is a rare disease, making it difficult to recruit high patient numbers. 
Therefore, international collaboration as seen in the European and American osteosarcoma 
study group (EURAMOS)-1 study is required. To date, the EURAMOS-1 has also been the 
largest clinical study conducted in osteosarcoma, achieved through the international 
collaboration of four multinational groups: Children’s Oncology Group, Cooperative 
Osteosarcoma Study Group (COSS), European Osteosarcoma Intergroup and Scandinavian 
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Sarcoma Group (109). Conducting clinical trials within such an international framework will 
enable future studies to be conducted under accepted standards, at higher speeds due to the 
large number of available patients and to also have higher statistical power to even detect 
small improvements in patient survival and compensate for the great heterogeneity of 
osteosarcomas. The EURAMOS-1 study represents the state of the art of osteosarcoma 
treatment and nicely illustrates current treatment-related complications as well as optimal 
survival rates with systemic MAP chemotherapy. One of the major aims of the EURAMOS-1 
trial (design shown in Fig. 4) was to evaluate if addition of interferon-α to MAP is beneficial 
after a good histologic response compared to state of the art MAP chemotherapy only (110).  
 
Figure 4. Trial design of the EURAMOS-1 osteosarcoma study. MAPifn: methotrexate, Adriamycin, 
cisplatin, interferon-α; MAPIE: methotrexate, Adriamycin, cisplatin, ifosfamide, etoposide. Figure adapted 
from (111) . 
At the time of trial initiation in 2005, only a limited amount of data about the effects of 
interferon-α on osteosarcoma development was available. It was shown in vitro that 
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interferon-α increased the sensitivity of osteosarcoma cells to cytotoxic drugs such as DOX 
and etoposide, but not towards CDDP, actinomycin D or vinblastine (112). Interferon-α also 
greatly inhibited the growth of transplanted human osteosarcoma cells in nude mice (113, 
114). At the same time, interferon-α treated tumors showed increased amounts of 
mineralized bone due to the interaction between osteosarcoma and its microenvironment, 
again shown in athymic mice (115). The in vivo data, however, was only derived from 
immunocompromised mice. Data from a Scandinavian clinical study demonstrated a trend 
towards better long term survival if higher amounts of interferon-α are given as a single 
adjuvant therapeutic. The patient cohort that trended towards better survival received larger 
doses of interferon-α, but also received a different pre-treatment (i.e. absence of radiation) as 
well as a different treatment after relapse compared to the earlier treated cohort (116). 
Similarly, a German clinical study tested the use of interferon-β in patients with localized 
primary osteosarcomas without detecting a significant clinical benefit (117).  
Based on the results described above, from in vitro studies and studies in nude mice as well 
as limited clinical information, the EURAMOS-1 trial was frivolously initiated. A total of 2260 
patients were recruited, with 716 patients being eligible for evaluation of the interferon-α-
treatment. However, evaluation of the current data failed to show a benefit for patient survival 
after addition of interferon-α (118). Perhaps, earlier addition of interferon-α (i.e. 
simultaneously to chemotherapy to improve synergy (112)) or the selection of a more 
appropriate cytokine (e.g. interferon-β has a more potent anti-osteoclastogenic effect (119); 
interferon-γ stimulates macrophages to inhibit osteosarcoma growth (97)) would have led to 
improved outcomes of combined immune-chemotherapy against osteosarcoma. In 
conclusion, an increasing knowledge about the complex interplay between immunotherapy - 
chemotherapy - osteosarcoma biology is required and sound preclinical models should be 
evaluated and employed before initiation of future clinical trials in order to assess new 
regimens with appropriate quality and acceptable standards. 
5.4.2 Mechanisms of current chemotherapeutics 
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Current chemotherapeutics used for osteosarcoma treatment target fast growing cells 
through interference with cellular replication. Therefore, also non tumor cells are affected by 
these compounds. CDDP is an inorganic complex, which exerts its toxicity after undergoing a 
spontaneous stepwise aquation reaction replacing its chlorine atoms (120). Once inside the 
nucleus, the monoaquated molecule preferably interacts with the N7-site of guanine forming 
mostly 1,2-intrastrand crosslinks (121). Consequently DNA damage sensors such as MSH2 
bind to the CDDP adducts halting the transcription machinery as well as inducing DNA 
damage signaling. On top of this, the cell cycle will be stopped to allow for nucleotide 
excision repair, specifically repairing intrastrand crosslinks. Ultimately, all signals seem to be 
integrated and linked via the tumor suppressor p53. Dependent on the intensities of each 
signaling pathway, the final fate of the cell is determined. In case of excess DNA damage, 
the equilibrium is shifted towards irreversible apoptosis.  
The anthracycline DOX and etoposide act through inhibition of topoisomerase II by 
intercalating with the DNA or without, respectively (122). Ultimately these topoisomerase II 
poisons lead to the formation of covalent protein-DNA complexes and the interference with 
processes such as DNA replication or transcription, ultimately resulting in apoptosis. 
Especially in the case of DOX, the topology of DNA is disturbed by evicting histones and 
increased torsional stress, causing double strand breaks. All of these events impair DNA 
repair and lead to apoptosis.  
Another DNA-crosslinking agent is ifosfamide. After cellular entry, its activated alkyl groups 
will mostly form DNA interstrand crosslinks (123). These crosslinks lead to the impairment of 
DNA strand separation during cell division and thus, induce tumor cell death (124). Apart 
from crosslinking DNA, ifosfamide was also shown to be involved in depleting protective 
glutathione levels leading to increased DNA alkylation and cytotoxicity (123). In contrast to 
above described chemotherapeutics, methotrexate does not interact with DNA, it acts via 
inhibition of dihydrofolate reductase. This enzyme is required to synthesize thymidylate, 
which is the substrate for thymidine production and hence, DNA synthesis (125). Newer 
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studies also demonstrated the interference of methotrexate with other cellular enzymes 
involved in energy production and redox balancing depleting NADPH levels. 
5.4.3 Side effects associated with current chemotherapeutics 
Although chemotherapy strongly increased overall survival, administration of MAP-
chemotherapy is limited by drug-specific toxicities leading, in the worst case, to patient death. 
Hematological toxicities are commonly observed with standard multidrug osteosarcoma 
chemotherapy, e.g. neutropenia (52-83% of patients), thrombocytopenia (28-50% of patients) 
and associated infections (58% of patients) (111, 126, 127). In addition to increased 
osteosarcoma patient survival rates, modern multidrug-chemotherapy also leads to the 
development of secondary neoplasms. Even years after completion of chemotherapy, 
secondary malignancies such as leukemia or breast cancer are observed in 1-9% of 
osteosarcoma patients (128-131). 
Some effects can be specifically ascribed to specific compounds of modern chemotherapy 
regimens. For instance, cardiac toxicity is associated with the administration of DOX (132). 
Ototoxicity and associated hearing loss is related to administration of CDDP and can be 
found in up to 11% of patients (133). Furthermore, renal failure is linked to administration of 
CDDP as a consequence of CDDP uptake by the proximal tubules and resulting tubular cell 
death (134, 135). However, advances in understanding the mechanism of nephrotoxicity and 
improved diuresis reduced the rates of cisplatin-specific renal failure under current clinical 
standards (111). CDDP was also shown to cause infertility in a dose dependent way in male 
patients (132). Acute and transient neurotoxicity can be observed after high dose 
methotrexate or ifosfamide (132). Similar to CDDP, high doses of methotrexate are linked to 
renal dysfunction in about 2% of osteosarcoma patients, due to the accumulation of 
methotrexate and its degradation products in the kidney (136). Altogether, systemic MAP 
chemotherapy and its management is an effective, yet aggressive treatment for patients and 
its use is limited by the chemotherapy-associated risks and patient discomfort. 
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In order to improve therapy efficacy without worsening side effects, new strategies are 
necessary. Approaches such as improved delivery of conventional drugs (achieved through 
e.g. targeting, liposomal packaging or local application) or the use of novel compounds are 
required. Ideally, such novel compounds have improved efficacy while inducing less side 
effects compared to currently used drugs and can therefore replace these drugs. 
Additionally, the targeted application of novel compounds, combined with standard, already 
effective drugs at equal or lower concentrations may improve the overall outcome. Some of 
these strategies to improve osteosarcoma treatment and their corresponding advantages are 
discussed in the following sections.  
5.4.4 Intraarterial chemotherapy 
Instead of intravenous (i.v.) drug administrations, local drug administrations via the tumor 
feeding artery present a more attractive alternative to common systemic administrations. 
First, such intraarterial (i.a.) drug applications are believed to achieve greater anti-tumor 
efficacy compared to systemic administrations, due to a first-pass effect by the tumor and 
subsequently higher intratumoral drug concentrations. At the same time, the resulting 
systemic drug concentrations will not be significantly reduced, if i.a. infused, and hence, no 
loss of systemic potency (= the ability to suppress metastases/ systemic disease) is present. 
Based on these favorable assumptions, potential benefits of i.a. administration of 
chemotherapeutics were first evaluated by Klopp et al. in 1950 (137). Tests using various 
animal models revealed a strong local effect of i.a. drug injections while the remaining 
tissues were spared from drug-induced damage. 
With respect to osteosarcoma, the first i.a. drug administrations were performed in the early 
1980s (138-140). Studies by Jaffe et al. and Stewart et al. confirmed a higher bioavailability 
of for instance CDDP after i.a. infusion (139, 141, 142), potentially leading to superior 
histologic response rates and superior survival rates with i.a. CDDP (142-144). Despite early 
trials of using i.a. DOX (145), among the standard drugs against osteosarcoma only CDDP 
continued to be infused i.a.. Using i.a. CDDP, Wilkins et al. achieved good histologic 
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responses in 87% of patients with localized osteosarcomas. In terms of good response rates, 
these results compare favorably to other clinical studies investigating localized osteosarcoma 
in similar patient cohorts treated with i.v. CDDP and i.v. doxorubicin (maximum percentage of 
patients with good response: 41%) (146), even with the use of a three/ four-drug regimen 
comprising methotrexate (maximum percentage of patients with good histologic response: 
71%) (10, 103, 118, 127, 146, 147). Also in a directly comparative study, i.a. CDDP showed 
superior histologic response rates compared to i.v. CDDP as part of a three-drug regimen 
(148). 
In compliance with the superior histologic response rates, studies from the St. Luke’s Medical 
Center achieved 10-year survival rates of  82% - 93% using i.v. doxorubicin and i.a. CDDP 
only (143, 149). These survival rates compare favorably to other studies with maximum 10-
year survival rates of, at best, 53- 64% with an i.v. two-drug regimen (35, 146) or up to 70% 
with an i.v. three/ four-drug regimen (4, 150). Notably, the improved survival rates achieved 
at the St. Luke’s Medical Center seem to be linked to high response rates due to the use of 
the two most active compounds in osteosarcoma treatment (CDDP and DOX) at high (local) 
doses. Furthermore, high histologic response rates were well reflected by the arteriographic 
responses (sensitivity of 98%). Therefore, surgery was performed as soon as an 
arteriographic response was achieved or the defined maximum number of courses was 
administered. The so achieved longitudinal monitoring of neoadjuvant chemotherapy 
outcome avoided unnecessary administration of further courses of chemotherapy, 
highlighting the general importance of longitudinal therapy response monitoring. 
Despite these positive associations with i.a. CDDP, a clinical trial evaluating tumor response 
according to the route of drug administration was not able to demonstrate unambiguous 
results in osteosarcoma patients (151). Notably however, patient survival was not evaluated 
in the course of this study. In another study, superior tumor responses with i.a. CDDP were 
only seen in the context of a three-drug regimen, whereas i.a. CDDP as part of a four-drug 
regimen did not yield significantly better responses compared to i.v. CDDP as part of the 
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same regimens (103). These studies demonstrate the difficulty of evaluating the “true” 
efficacy of i.a. CDDP due to confounding factors such as administration of combinations of 
chemotherapeutics, tumor heterogeneity side effect management as well as interinstitutional 
differences, parameters inherently present in any clinical study environment.  
5.4.4.1 Side effects of i.a. CDDP 
Besides improved tumor response and survival rates of osteosarcoma patients, i.a. CDDP 
also generates a different spectrum of side effects compared to equivalent doses of i.v. 
chemotherapy. In a study comparing i.v. and i.a. application of CDDP in head and neck 
cancer, a reduction of nephrotoxicity was observed, but also a simultaneous increase of 
neurological toxicities (152). In another study, again in head and neck cancer, increased 
rates of cerebral infarction were observed after i.a. chemotherapy, while frequencies of 
systemic toxicities such as mucosal toxicity or febril neutropenia were not different (153). 
Similarly, no differences in systemic toxicities were observed between i.a. versus i.v. 
chemotherapy in glioblastoma (154). In a study comparing i.v. and i.a. chemotherapy in 
metastatic brain tumors, myelosuppression was worse in the i.v. treatment arm, while other 
systemic toxicities were similar (155). In contrast, local toxicities were only observed with i.a. 
chemotherapy.  
When considering studies with osteosarcoma patients only, no differences in nephrotoxicity 
were detected. Similarly, no significant differences in hematological toxicities dependent on 
the route of administration of CDDP as part of a three-drug regimen were detected in a study 
performing a direct comparison of i.v. versus i.a. CDDP (103). Furthermore, i.a. CDDP 
specifically affected the skin close to the infusion site by inducing local swelling and skin 
necrosis in 6-8% of the patients (103, 151). Myocutaneous inflammation, another i.a. CDDP 
specific side effect, was observed in 6% of the patients (149). Other frequently reported 
toxicities observed with i.a. CDDP and simultaneous administration of common 
chemotherapeutics are mostly similar to systemic chemotherapy only; for instance: 
mucositis: 27% (with i.a. CDDP) versus 27%-common (with i.v. CDDP); neutropenia: 
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infrequent versus 58-89%; death due to chemotherapy: 0% versus 0.13-2.8%; leukopenia: 
2% versus 79%; thrombocytopenia: 7% versus 52% (103, 104, 108, 111, 143, 149). Although 
some chemotherapy-related side effects such as death, thrombocytopenia or leukopenia 
might seem to be reduced with i.a. chemotherapy in osteosarcoma, a direct comparison as 
presented above is difficult because most parameters were not directly compared within the 
same study. Thus, interinstitutional differences such as treatment regimens, side effect 
management or different toxicological grading schemes need to be considered. 
5.4.4.2 I.a. chemotherapy in pre-clinical models 
Due to the rarity of osteosarcoma, patient numbers are generally low. To improve the 
understanding of osteosarcoma without having high numbers of patient samples available, 
researchers often employ animal models to test novel therapeutics or diagnostics. Similarly, 
i.a. drug administrations were assessed using preclinical animal models of osteosarcoma 
and other cancers. 
Similar to humans, dogs develop osteosarcomas spontaneously, yet at a ten times higher 
frequency (156). The spontaneous occurrences as well as the resemblance of the human 
disease in terms of sites of metastasis, sites of primary tumor growth and identical histology 
of the disease render canine osteosarcomas a valuable “clinical intermediary” for the study of 
the human disease (157). Based on the characteristics of canine osteosarcomas, Powers et 
al. conducted a study comparing i.v. and i.a. CDDP in dogs bearing spontaneous 
osteosarcomas (158). Although no obvious difference was found with respect to time to 
metastasis, the study showed superior histologic responses when CDDP was infused via the 
tumor feeding artery (49% mean percentage of necrosis) compared to i.v. CDDP (23.8%) 
infusions. In line with Powers et al., a study of spontaneous head and neck squamous cell 
carcinomas in sheep employed CDDP as a reference drug and demonstrated objective 




Also studies of other cancers pointed at an increased tumor perfusion of radiolabeled drug 
using i.a. infusions (160). In addition, they also explained a decrease in radioactivity of the 
tumor periphery as well as necrotic areas by a reduced local blood flow. Hence, monitoring of 
the tumor blood flow is desired to estimate the efficacy of i.a. chemotherapy, as also clinically 
demonstrated by Wilkins et al. (described above (143)).  Similarly, Takeda et al. showed 
improved tumor control of i.a. chemotherapy over i.v. chemotherapy in a transplant model of 
rat brain tumors (161). To also prove validity in human glioma xenografts, an athymic rat 
model was applied by Schuster et al. (162).  In addition to superior glioma control, i.a. 
chemotherapy also significantly increased survival of the rats, when compared to i.v. 
administrations of a similar or even a two-fold higher dose.  
5.4.4.3 Conclusions 
In summary, preclinical and clinical studies evaluating i.a. administrations of 
chemotherapeutics have demonstrated the feasibility of such. Especially in osteosarcoma of 
the extremities, the use of i.a. chemotherapy through the tumor-feeding artery seems to be 
advantageous, due to higher drug concentrations within the tumor, a similar if not an 
improved spectrum of side effects compared with systemic chemotherapy and the avoidance 
of severe local side effects such as seen after i.a. chemotherapy against malignancies of the 
brain. Despite proof for improved histologic responses and indications for improved survival 
rates, the broad use of i.a. chemotherapy in clinical settings has ceased during the last two 
decades. Mostly reasons such as higher demand on technical requirements, the standard 
use of multi-agent chemotherapy (103) or the focus on a systemic effect of chemotherapy 
rather than local control (151) led to the discontinuation of evaluating i.a. administrations of 
chemotherapeutics. Opposing these assumptions, a better histologic response after i.a. 
chemotherapy might compromise the remaining primary tumor’s ability to seed lung 
metastases and thus, impact patient survival in the long run. In conclusion, i.a. administration 
of cytotoxic chemotherapy may be considered for patient treatment as long as there are no 
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osteosarcoma-specific drugs available in order to improve local tumor control and reduce 
severe systemic side effects. 
5.4.5 Immunotherapy 
The immune system (both innate and adaptive) imposes a constant selection pressure on 
developing cancers. At all stages of cancer progression, osteosarcoma cells have to 
constantly avoid detection and destruction by the cells of the immune system. Due to the 
promising long-lasting anti-cancer effects, immunotherapy has already sparked interest in the 
19th century, most prominently through the work of William B Coley  (163). Back then, Coley 
produced a mixture of heat-inactivated gram-negative as well as gram-positive bacteria 
(“Coley’s Toxins”) that induced a potent infection leading to exceptional regressions of 
tumors, especially of soft tissue sarcomas. These early successes were most often observed 
with sarcomas, with about 50% showing long lasting responses (i.e. patients rendered free of 
disease >5 years). Despite the observed toxicities, these “artificial infections” also showed 
the huge potential of immunotherapy in achieving long lasting cures. Although inoperable 
bone cancers showed a great diversity of responses (ranging from poor to good responses) 
to Coley’s Toxins (163), more recent studies demonstrated evidence in favor for the use of 
immunotherapy against osteosarcoma. Two studies investigating spontaneous 
osteosarcomas in dogs discovered prolonged survival times if the dogs suffered from a 
postoperative infection or if they were treated with an inflammation-inducing compound (164, 
165).   
One of the latest examples that demonstrated the immune system’s power is the use of 
liposomal muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) against human 
osteosarcoma (166). L-MTP-PE was already approved by the European Medicines Agency 
(EMA) for use against nonmetastatic osteosarcoma and is thought to act via activation of 
macrophages and monocytes (167). It was also shown to elevate TNF-α as well as IL-6 
plasma levels shortly after administration of L-MTP-PE, in turn causing chills and fever (168).  
Already in the late 1980s, L-MTP-PE was tested in canine osteosarcoma patients and 
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achieved outstanding effects by almost tripling the median survival time of dogs compared to 
a nontreated control cohort (169). Most importantly, administration of L-MTP-PE led to a 
significant improvement in overall survival if administered with standard chemotherapy (from 
70% using standard chemotherapy to 78% with the addition of L-MTP-PE), the largest, 
significant improvement in patient survival in a randomized phase III trial of osteosarcoma 
since the introduction of multi-drug chemotherapy (170). Other support for the applicability of 
immunotherapy against human osteosarcoma is the observation that osteosarcoma patients 
have an improved survival rate after obtaining a postoperative infection compared to non-
infected ones (34). In addition, the early recovery of lymphocytes (37), a higher number of 
pre-surgical lymphocytes (171) as well as a higher ratio of CD8+/FOX3P+ lymphocytes (172) 
were shown to be prognostic for improved survival of osteosarcoma patients.  
These studies point to a benefit for osteosarcoma patients through immunotherapy and, in 
light of the plateaued patient survival with the use of chemotherapeutics, support further 
studies evaluating the full potential of immunotherapeutic approaches against osteosarcoma.  
5.4.5.1 TNF-α: general functions and role in cancer therapy 
Until 1975 endotoxin was thought to cause hemorrhagic necrosis of tumors. However, 
Carswell et al. identified the active ingredient that caused tumor necrosis in sera of bacillus 
sp. infected and endotoxin treated mice and termed it “Tumor necrosis factor”(TNF) (173). 
More importantly, they also discovered that TNF is actually produced by the host and not 
contained in the endotoxin itself. Nowadays, it is known that members of the TNF-
superfamily are active in a trimeric form and can be found either soluble or bound to the cell 
surface (174). TNFs are very potent pro-inflammatory cytokines (stimulate T and B 
lymphocytes, as well as antigen presenting cells (APC), e.g. dendritic cells) explaining the 
success of anti-TNF therapy as treatment against various autoimmune diseases (e.g. 
rheumatoid arthritis (175), Crohn’s disease (176, 177)).  
One of the most prominent members of the TNF superfamily is the type II transmembrane 
protein TNF-α which is mostly produced by macrophages and T lymphocytes (178, 179). 
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After cutting of the membrane bound TNF-α via TNF-α converting enzyme (TACE), soluble 
TNF-α will bind to TNF receptor 1 (TNFR1) and mostly induce pro-inflammatory as well as 
the programmed cell death pathways (179, 180). In contrast, transmembrane TNF-α is 
superior to its soluble form in binding to TNFR2 that is mainly expressed by immune cells 
and endothelial cells and thus, evoking signaling cascades leading to T cell activation, 
thymocyte proliferation and granulocyte/macrophage colony-stimulating factor (G/ M-CSF) 
production (181). Therefore, TNF-α signaling via TNFR1 is usually associated with cytotoxic 
and pro-inflammatory signaling whereas TNF-α signaling via TNFR2 is rather associated with 
cell migration, activation and proliferation (179). Furthermore, systemic TNF-α signaling 
during inflammation leads to vasodilation (182), disruption of the integrity of the endothelial 
monolayer (183), edema formation and the adhesion of leukocytes (184). On the one hand, 
the strong pro-inflammatory capability of TNF-α render it an interesting candidate for anti-
cancer (immuno)therapy. On the other hand, approximately 15% of cancers are attributable 
to infections and underlying inflammations (185). Besides forming a cancerogenic 
inflammatory environment, chronic inflammation also commonly induces bone resorption 
(186). Especially in the case of osteotropic malignancies such as osteosarcoma, chronic 
inflammation or immunotherapy must be well controlled, because of its potential in promoting 
the vicious cycle of bone remodeling and thus, osteosarcoma progression (187). In general, 
local concentrations of TNF-α are critical. Locally high concentrations of TNF-α induce tumor 
necrosis and locally low and chronic concentrations promote tumorigenesis (188).  
Experiments in the 1980s demonstrated promising anti-tumor effects of TNF-α against 
experimental sarcomas (189). However, in order to cause complete tumor necrosis, TNF-α 
was dependent on its ability to destroy the tumor vasculature (190) and the presence of 
tumor-specific immunity (191, 192). These results are further supported through in vitro tests 
where TNF-α required an additional stressor such as actinomycin-D to induce broad tumor 
cell death (188). Despite the impressive anti-tumor effects of TNF-α against cancers, its 
systemic use is limited by severe toxicities- similar to the administration of Coley’s Toxins. 
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TNF-α can induce shock, tissue injury, gastrointestinal necrosis, acute renal tubular necrosis, 
among others, even at TNF-α levels which could be endogenously produced by the host 
(193).  
In order to overcome these important limitations, researchers started to investigate the 
potential of isolated limb perfusions  (194, 195), local delivery of the TNF-α gene via 
intratumoral injections (196), modification of the TNF-α protein to be less toxic (197) or by 
adding a targeting moiety (198). To date, isolated limb perfusion (ILP) of TNF-α and 
melphalan demonstrated feasibility and indicated clinical success in treatment of advanced 
soft tissue sarcomas and melanomas (195, 199, 200). A feasibility study, testing ILP with 
TNF-α and CDDP in dogs with spontaneous osteosarcomas, was marked by a high mortality 
rate (201). In humans, treatment of osteosarcoma using ILP with TNF-α, melphalan and 
interferon-γ showed high percentage of tumor necrosis despite absence of significant tumor 
shrinkage (202). In addition, the remaining tumors formed a thick collagen-I capsule which 
facilitated surgical removal of the primary tumor. However, similar to the dog study described 
above, mortality of ILP with TNF-α in human osteosarcoma patients was high (62% died 
within 1 year) (203). Thus, the use of ILP with TNF-α as a treatment strategy remains to be 
only used by single specialized institutions. Likewise, intratumoral injections are not 
commonly used in clinics as a route of drug administration due to the relatively uncontrolled 
delivery (similar to intraperitoneal  (i.p.) injections). In conclusion, the only direct means of 
ultimately administering TNF-α to patients without evoking severe sepsis is the modification 
of the biologically active compound, for instance through addition of a targeting moiety. 
5.4.5.1.1 TNFα in osteosarcoma  
Preclinical studies mostly reported conflicting results about the efficacy of TNF-α against 
osteosarcomas. For instance, experimental studies demonstrated tumor-promoting abilities 
of TNF-α addition, reflected by an increased metastatic potential (204, 205), being non-
responsive to TNF-α induced cell death or maintaining osteosarcoma cells in an 
undifferentiated state (206). In a rat in vivo model, experimental osteosarcomas showed no 
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response upon TNF-α ILP (with melphalan) due to a claimed lack of immunogenicity and a 
relatively low microvessel density (207). In contrast, the same osteosarcoma cell line showed 
growth retardation if subcutaneously (s.c.) implanted and treated with ILP of TNF-α and 
DOX, likely, because of increased intratumoral DOX concentrations (208). Clear 
immunotherapeutic potential and involvement of TNF-α in the treatment of osteosarcomas 
was demonstrated in a study using microwave ablated osteosarcoma cells, used as a 
vaccine to inhibit tumor growth in mice (209). At the same time, microwave ablation in situ 
actively protected rats from further tumor growth due to rejection by the immune system after 
TNF-α stimulation. These conflicting results might be explained by the fact that these 
experimental models used artificial microenvironments (i.e. in vitro or s.c./ i.p. xenografts), 
whereas it would be more clinically relevant to assess the effect in a bony microenvironment. 
In summary, systemic TNF-α or ILP with TNF-α do not seem to be appropriate for human use 
without further adaptations. 
5.4.5.1.2 Targeted formulations of TNF-α  
The actual anti-tumor effect of TNF-α is exerted through indirect effects (210) such as 
disturbance of the tumor vasculature integrity (183) or stimulation through its immune 
activating properties (191, 211). The tumor or host derived endothelial cells and precursors 
can be destroyed through the action of TNF-α (191, 199) or become activated to induce 
blood coagulation (212). These desired effects of TNF-α on the tumor vasculature are further 
amplified through addition of targeting moieties (e.g. NGR (a common peptid motif on 
neovasculature), F8 (targets the EDA domain of fibronectin), L19 (targets the EDB domain of 
fibronectin), TCP-1 (a peptide motif targeting vasculature of colorectal cancers)), with the aim 
of minimizing its systemic toxicity through tumor-/ neovasculature targeted delivery (198, 
213-215). TNF-α itself also increases the permeability of blood vessels or increases their 
stability dependent on its local concentration (183, 216). Considering the effects of TNF-α on 
the tumor vasculature, co-administration of TNF-α with chemotherapeutics has the potential 
to increase the intratumoral concentration of drugs (208) and consequently, enhance their 
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potency (189, 217). Most importantly, targeting of TNF-α allowed the systemic application of 
the cytokine at efficacious concentrations, without causing systemic toxicity (213). 
5.4.5.2 Immunostimulatory characteristics of conventional chemotherapy 
Against the assumption of mostly direct cytotoxic effects of conventional chemotherapy on 
tumor cells without an obvious link to the host’s immune system, more and more evidence 
accumulates for the importance of such a connection. In fact, the presence and composition 
of immune cells in the tumor bed strongly influences pathologic tumor responses as well as 
cancer patient survival (218-220). Likewise, the absence of lymphocytes in the blood has a 
negative influence on patient survival. As demonstrated in soft tissue sarcoma, breast cancer 
and lymphoma, lymphopenia (<1000 lymphocytes/μl) is a strong prognostic factor for poor 
overall survival (221). Initially, chemotherapeutics were selected and tested based on their 
direct tumoricidal effects. However, most of these drugs (>50%) were recently shown to have 
at least some influence on the host immune system, even below tumoricidal concentrations 
(e.g. a concentration dependent effect on maturation/ cell death of DCs (222)). Especially 
conventional and already successful chemotherapeutics such as anthracyclines (e.g. DOX) 
or oxaliplatin (not CDDP), also act as potent immunotherapeutics. Anthracyclines were 
shown to naturally evoke an immunogenic cell death (ICD) response dependent on 
endoplasmatic reticulum (ER) stress signaling (223). This ICD is dependent on the action of 
TLR4+ dendritic cells (DC) and cytotoxic CD8+ T lymphocytes (224). In contrast to DOX, 
CDDP or mitomycin C by themselves are not capable of inducing ICD (225). However, 
induction of ER stress signals such as translocation of calreticulin from the lumen of the ER 
to the cell surface (e.g. by digoxin treatment) in combination with CDDP treatment is capable 
of inducing ICD (226). Expression of calreticulin (or HSP90) on the cell surface of dying 
tumor cells leads to antigen engulfment by DC and maturation of DC for proper tumor 
antigen presentation and mounting tumor-specific immune responses via CTLs (227, 228).  
Other than altering the host’s immune system, immunotherapy (e.g. TNF-α) and 
chemotherapy can be combined to evoke beneficial microenvironmental changes. For 
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instance, TNF-α was shown to synergistically cause increased necrosis in sarcomas as well 
as osteosarcoma animal models if applied together with DOX or other chemotherapeutics 
(189, 208, 229, 230), which can be explained by the disruption of the endothelial layer due to 
co-administration of TNF-α, leading to enhanced vascular leakage and increased 
intratumoral DOX concentrations (183, 208, 230).  
5.4.5.3 Conclusions 
In summary, improving immunotherapy of osteosarcoma has the potential to increase patient 
survival. However, the main requirement for future therapies to be successful is a better 
understanding of the interplay between the immune system and the microenvironment of 
bone. For instance, similar to the “malignant” vicious cycle (see Fig. 1), an inflammation-
induced vicious cycle (i.e. by T lymphocytes) can also cause bone resorption. Not only 
RANKL from T lymphocytes, but also expression of TNF-α due to chronic inflammatory 
conditions (e.g. rheumatoid arthritis) leads to activation of osteoclast activity and hence, bone 
resorption (231). Ultimately, the precise role (i.e. inhibitory or activating) of TNF-α on 
osteoblast activity depends on the local tissue concentration as well as the expression state 
of the osteoblast (232). These examples nicely demonstrate the importance of understanding 
the role of inflammatory signaling in the context of bone remodeling. Last but not least, the 
effects of conventional chemotherapeutics need to be discovered with respect to their 
immune effects. Knowing the concentrations at which chemotherapeutics achieve optimal 
immunostimulatory effects will allow the tailored application of backbone chemotherapy to 





6 Aims of the thesis 
Chemotherapy is the mainstay of osteosarcoma therapy besides surgical removal of the 
tumor. In contrast to surgery, chemotherapy not only impacts the primary tumor or large, 
resectable metastases, it also hinders the growth or even eradicates micrometastatic 
disease. Already four decades ago, the introduction of chemotherapy led to the largest 
improvement of survival rates in osteosarcoma. In order to build upon the success of already 
established chemotherapeutics, the major goal of this work is to (re)assess modern 
chemotherapy from a today’s point of view. Specifically, is there a way to optimize current 
combinatorial practices to improve their overall therapeutic efficacy? 
 In order to answer these questions, our work is divided into three sub aims: 
1- Effect of standard chemotherapy on biomarkers in human osteosarcoma tissue. The 
expression of biomarkers associated with therapy outcome may help to stratify patients, 
ideally at diagnosis, to receive an adapted chemotherapy schedule according to the 
aggressiveness of the disease. This helps to avoid administration of chemotherapy to 
patients that might not benefit based on their biomarker profile and thus, spares them from 
the associated side effects. In order to obtain the necessary knowledge about potential 
biomarkers of a rare cancer such as osteosarcoma, an optimal use of the available tumor 
tissue is required. To achieve this goal, we investigated the impact of conventional 
chemotherapy on the expression of specific biomarkers (e.g. tumor suppressors) by using a 
tissue microarray to study the expression of selected biomarkers in human osteosarcoma 
samples prior to and after chemotherapy. 
2- Increasing the anti-tumor efficacy of conventional chemotherapy without 
decreasing its systemic potency.  Intraarterial drug administrations via the tumor feeding 
artery allow for higher regional drug concentrations. It is believed, that i.a. CDDP is superior 
to i.v. CDDP in terms of tumor control. However, clinical studies so far could not show a true 
benefit of i.a. over i.v. CDDP administration. Furthermore, little is known about the impact of 
i.a. CDDP on the development of pulmonary metastasis. Therefore, we used a mouse model 
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of experimental metastatic osteosarcoma to compare the effects of i.a. with i.v. CDDP-based 
chemotherapy on osteosarcoma development, including its associated toxicities. 
3- Combining conventional chemotherapy with a novel immunotherapeutic drug 
against metastatic osteosarcoma. The use of conventional chemotherapy improved overall 
patient survival compared to surgery alone. Five-year survival rates plateaued at 60-70% for 
localized disease, whereas survival rates for metastatic osteosarcomas remain at a low 20%, 
despite the use of highly cytotoxic chemotherapy. Therefore, novel approaches to target 
metastatic disease are urgently needed. Based on initial preclinical successes in soft tissue 
sarcomas, we believe that TNF-α also has the potential to treat osteosarcomas. To this end, 
we evaluated the effect of a vasculature-targeted version of TNF-α (F8-TNF) using a 
syngeneic metastatic mouse model.  First, drug efficacy was evaluated in the presence of a 
primary tumor. Next, efficacy of F8-TNF, alone or with DOX, was evaluated in a syngeneic 
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7.1.1 Additional files 
 
Additional file 1. Positive, cytoplasmic only P16 immunostaining. This figure displays an 
immunostaining of P16 which is solely present in the cytoplasm of tumor cells (arrows point 
at representative cancer cells). The blue color of all nuclei is never fully covered with brown 






Additional file 2. Kaplan- Meier survival analysis of samples grouped according to 
subcellular localization of P16. P16 positive samples were grouped according to the 
subcellular localization of P16, yielding “cytoplasmic and nuclear” (cn) P16 as well as 
“cytoplasmic only” (c) P16. (A) Kaplan-Meier plot showing no difference in survival rates of 
BXs stratified according to c or cn subcellular localizations of P16 (P = 0.358). (B) Kaplan-
Meier survival analysis using RXs yielded similar survival rates of cn and c P16 (P = 0.845). 
In contrast, cnP16 and cP16 showed worse survival rates when compared to P16 negative 
samples (P = 0.067 and P = 0.059, respectively). Abbreviations: BX, biopsy; c, cytoplasmic 
only; cn, cytoplasmic and nuclear; RX, resection; 
 
  




Additional file 3. Correlations between Ki67 IHC and IHC of other 
biomarkers 
   BX    RX   
Maspin neg pos 
 
Maspin neg pos
Ki67 neg 11 5 
P < 
0.001 12 2 P = 0.008 
pos 1 21 2 6 
PTEN neg pos  PTEN neg pos
Ki67 neg 10 6 
P = 
0.018 11 2 P = 0.046 
pos 5 19 2 4 
P53 neg pos  P53 neg pos
Ki67 neg 15 4 
P = 
1.000 11 6 P = 0.667 
pos 20 4 4 4 
P16 neg pos  P16 neg pos
Ki67 neg 10 7 
P = 
0.050 8 7 P = 0.086 
pos 6 18 1 7 
BMI1 neg pos  BMI1 neg pos
Ki67 neg 17 0 
P = 
0.001 11 2 P = 0.505 
pos 12 11 8 0 
Abbreviations: IHC, immunohistochemistry; neg, negative; pos, positive. 
 
7.1.2 Additional study: cytoplasmic p16 in osteosarcoma 
Based on the relevance of cytoplasmic p16 (cytP16) in osteosarcoma therapy as 
demonstrated in our manuscript, we started investigating the role of cytP16 in vitro using 
human osteosarcoma cell lines. Especially the impact of cytP16 on chemoresistance was 
started to be investigated. 
7.1.2.1 Materials and methods 
7.1.2.1.1 Immunofluorescence 
Cells were seeded on glass cover slips 24 h before staining, cultured in DMEM (4.5 g/l 
glucose)/HamF12 (1:1) medium (Invitrogen, Carlsbad, CA, USA), supplemented with 10% 
heat-inactivated FCS (GIBCO, Basel, Switzerland). After 10 min of fixation with 4% 
paraformaldehyde, cells were permeabilized with NP40 (Nonidet P40, Sigma-Aldrich, St. 
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Louis, MO, USA)and blocking with 3% bovine serum albumin (BSA, Sigma-Aldrich) and 
0.01% Triton X-100 (Sigma-Aldrich) in PBS was performed.  Anti-p16 mouse monoclonal 
antibody (JC8, sc-56330, Santa Cruz Biotechnology, Inc., Dallas, TX, USA; 1:100) (233), 
Hoechst (Invitrogen; 1:1000) and an Alexa488-coupled secondary anti-mouse antibody (Life 
Technologies, Carlsbad, CA, USA; 1:200) were used to visualize the localization of p16. 
Images were acquired using an Axio Observer Z1 microscope (Zeiss, Oberkochen, 
Germany) and an Andromeda spinning disc confocal microscope (FEI Munich, Gräfelfing, 
Germany) and processed using ImageJ v1.47 (U. S. National Institutes of Health). 
7.1.2.1.2 WST-1 assay 
WST-1 cell proliferation assay (Roche, Mannheim, Germany) was performed according to 
the manufacturer’s instructions. Briefly, cells were cultured in medium for 24 h before CDDP 
(Sandoz) dissolved in cell culture medium was added. After 24 h and 48 h of drug treatment 
WST-1 reagent was added and 3 h later absorption at 450 nm using a Synergy HT 
spectrophotometer (BioTek, Winooski, VT, USA) was measured. Dose-response curves and 
IC50-values were calculated using Prism 5 v5.01 software (GraphPad Software, Inc., La 
Jolla, CA, USA).  
7.1.2.1.3 Western blot 
Cell extracts were produced using the REAP method (234) and a cell disruptor W375 
sonicator (Heat Systems Ultrasonics, Inc.). Equal amounts of cells were used for extraction 
and extracted proteins were separated by 10% SDS-PAGE. The proteins were then 
transferred by semi-dry blotting to Hybond-ECL membranes (GE Healthcare, Glattbrugg, 
Switzerland). Actin (anti-beta actin, MAB1501, Merck Millipore, Darmstadt, Germany; 1:10 
000) and p16 (JC8, Santa Cruz Biotechnology, 1:200) were detected with the indicated 
antibodies and visualized using horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Santa Cruz Biotechnology) as well as the Immobilon chemiluminescence 
substrate (Merck Millipore) and detected with a ChemiDoc Imaging System (Bio-Rad, 




In order to characterize the protein expression of p16 in various osteosarcoma cell lines, we 
selected a panel of established osteosarcoma cell lines (SaOS2, G292, HuO9, MG63, 143B 
(HOS-derived) and U2OS) according to their p16 status (235) and evaluated p16 expression 
using immunofluorescence analysis (Fig. 1).  
 
Figure 1. Immunofluorescence of six osteosarcoma cell lines. The left column shows p16+ osteosarcoma cell 
lines and the right panel shows p16- osteosarcoma cell lines (original magnification 200 X). Scale bar corresponds 
to 100 μm.  
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 After the pre-selection using fluorescence microscopy, the  cytoplasmic localization of p16 in 
G292, HuO9 and SaOS2 was confirmed using confocal microscopy (Fig. 2). 
 
Figure 2. Immunofluorescence of cytoplasmic p16 in three osteosarcoma cell lines. Confocal microscopy 
images confirming the cytoplasmic subcellular localization of p16+ cell lines (original magnification 200 X). Scale 
bar corresponds to 100 μm. 
Next, we wanted to see if the expression of cytP16 is affected by CDDP treatment. First, the 
resistance of p16+ osteosarcoma cell lines against CDDP was tested and IC50 values were 




Figure 3. Dose-response curves of cytP16
+
 cell lines to CDDP treatment. Inhibition of cell growth after 
addition of various concentrations of CDDP was measured using WST-1 assay after 72h for A, G292; B, HuO9; 
and C, SaOS2.  
To test whether cytP16 is affected by CDDP, we quantified the changes of protein 
expression after different periods of treatment with CDDP at concentrations close to the cell 
line-specific IC50 values. Therefore, western blot analysis of fractionated cell extracts was 
performed (Fig. 4). Quantification of the western blot analysis showed a CDDP-dependent 
increase of cytP16 in the cytoplasmic fraction of G292 and HuO9 cells over time compared 
with the corresponding control cells (Fig. 5). In contrast, SaOS2 cells did not reflect a linear 




Figure 4. Western blots of p16 in osteosarcoma cell lines. SaOS2 cells (black bars) were treated with two 
different concentrations of CDDP (0.5 μg/ml or 2 μg/ml). HuO9 (white bars) and G292 (grey bars) were treated 
with 0.5 μg/ml of CDDP. Whole cell extracts (WCE), cytoplasmic fractions (Cyt) and nuclear fractions (Nuc) were 
blotted, derived from control cells and CDDP-treated cells at different time points. Actin was used as a loading 
control. 







































































































































































Figure 5. Quantification of western blot analysis of cytP16 after CDDP treatment. Values on the y-axis 
represent normalized changes of cytP16 (i.e. cytP16 / actin) with respect to the corresponding control (i.e. 24 h 
CDDP treated / 24 h vehicle treated). CytP16 levels of osteosarcoma cells after 0 h were normalized to 1.  
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7.1.3 Discussion and conclusion 
The role of cytP16 in cancer is still not entirely understood. Only in the 2000s, studies 
demonstrated the presence of cytP16 (236), without regarding cytP16 as background-
staining any longer (237). By using a specific anti-human p16 antibody (233), our results also 
showed that the presence of cytP16 in osteosarcoma cell lines is not an artifact. Of the few in 
vitro studies conducted on cytP16 in cancer, cytP16 was found to be present in two different 
forms and both were able to bind cyclin-dependent kinase 4/6 (cdk4/6) (238). It was also 
suggested that p16 is secreted to the cytoplasm by cancer cells to avoid its proliferation-
inhibiting effects within the nucleus (239). Other studies have shown that cytP16 is capable 
of stimulating migration (240) or proposed to play a role in chemoresistance, yet without 
showing experimental evidence (241). The results from our human osteosarcoma tissue 
microarray (TMA) study also suggested a role of cytP16 in chemoresistance, and 
demonstrated a link between cytP16 and patient survival (242).  
To see the influence of CDDP on cytP16, we assessed cytP16 expression levels after 
treatment of osteosarcoma cell lines with the corresponding IC50 of CDDP. Subsequently, 
subcellular fractionation of three cell lines possessing endogenous expression of cytP16 was 
performed and the amount of cytP16 was quantified. Our results showed that if Hu09 or 
G292 cell lines were treated with a CDDP concentration close to the IC50 value, the relative 
amounts of cytP16 increased over time, demonstrating a link between cytP16 and response 
to chemotherapy. In contrast, SaOS2 cells did not show a similar change of cytP16 after 
CDDP treatment. However, these results need to be repeated and confirmed in future 
studies. Additional experimental studies are required to assess the importance of altered 
levels of cytP16 in chemoresistance and to assess corresponding proteomic changes. Future 
studies might employ G292, SaOS2 and HuO9 osteosarcoma cell lines which can be 
induced to overexpress/ or lose cytP16 in order to study the effects of cytP16 in more detail 
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7.2.1 Additional files 




50 - 90% tumor 
necrosis 
< 50% tumor 
necrosis 
i.a. CDDP 11 5 3 3 
i.a. vehicle 6 0 2 4 
i.v. CDDP 6 0 0 6 
i.v. vehicle 6 0 0 6 
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1 Abstract 
In osteosarcoma, the most frequent cause of death is the development of pulmonary 
metastases. Nevertheless, most experimental drugs are evaluated by measuring primary 
tumor growth in various experimental systems. Extra-domain A (EDA)-targeted tumor 
necrosis factor α (F8-TNF) already showed promising anti-tumor effects against experimental 
sarcomas. Using K7M2L2, a K7M2-derived orthotopic syngeneic model of osteosarcoma, we 
evaluated the efficacy of F8-TNF against primary tumors and pulmonary metastases. 
Primary tumor growth was not affected by F8-TNF. However, numbers of pulmonary 
micrometastases were reduced, likely due to an F8-TNF-dependent activation of pulmonary 
CD4+, CD8+ and natural killer cells. Furthermore, histological analysis revealed stronger 
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expression of EDA in pulmonary metastases compared with primary tumor tissue. EDA 
expression was found to be dependent on the microenvironment as well as the growth of 
metastases. Immunofluorescence using human osteosarcoma tissue confirmed the presence 
of EDA in primary tumors as well as metastases. To further study pulmonary metastatic 
growth, an amputation model was established to evaluate the efficacy of F8-TNF, as single 
treatment or combined with doxorubicin, against established pulmonary metastases. Despite 
presence of EDA in metastases, no significant inhibitory effect of F8-TNF or combination 
treatment on further growth of late pulmonary metastases was detected and no significant 
difference in numbers of CD4+ or CD8+ cells in the lungs were observed. Interestingly, F8-
TNF treatment led to significantly enlarged spleens, whereas addition of doxorubicin 
attenuated this effect. These findings demonstrate the potential of F8-TNF in reducing early 
metastatic growth yet suggest a lack of efficacy of F8-TNF alone or combined with 
doxorubicin against established pulmonary metastases. Further studies are required to 
improve targeted-immunotherapy against metastatic osteosarcoma.  
 
2 Introduction 
Primary bone cancers, with osteosarcoma as its most common representative, are among 
the deadliest cancers in children and adolescents [1, 2]. Following the introduction of 
chemotherapy in the 1970s, five-year survival rates of osteosarcoma increased significantly, 
except for  patients with metastatic disease, which remained at a low 20% until today [3]. 
While the primary tumor can be effectively treated using modern multidrug chemotherapy 
schemes (i.e. doxorubicin (DOX), methotrexate, cisplatin) and surgery, metastatic disease is 
inefficiently treated and thus, remains to be the strongest prognostic factor for poor patient 
survival [4].  
A promising approach against metastatic osteosarcoma may be the induction of an immune 
reaction towards the disseminated cancer cells. To date, several studies demonstrated 
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improved survival rates of osteosarcoma patients after standard chemotherapy if hallmarks 
of an activated immune system are present. For instance, postoperative infections in non-
metastatic osteosarcoma patients [5] as well as a high ratio of intratumoral CD8+/FOX3P+ 
lymphocytes [6] were found to be prognostic for improved survival rates of osteosarcoma 
patients. In addition to improved survival rates, early recovery of lymphocytes after 
neoadjuvant chemotherapy was also indicative for fewer relapses [7]. Similarly, a higher pre-
surgical lymphocytes to monocytes ratio was associated with better survival rates as well as 
a lower frequency of metastases at diagnosis [8]. Furthermore, already established 
chemotherapeutics such as anthracyclines (e.g. DOX) act as inducers of immunogenic cell 
death, further potentiating an anti-cancer immune response [9]. These studies point to a 
survival benefit for osteosarcoma patients mediated through the cytotoxic actions of 
chemotherapy on the one hand and a competent immune system on the other.  
In order to further enhance chemotherapy-induced immune responses a potent cytokine can 
be employed. One of the most potent pro-inflammatory cytokines is tumor necrosis factor-α 
(TNF-α), which contributed to great anti-tumor effects against sarcomas and lymphomas 
already around 1900 [10, 11]. The anti-tumor effects of TNF-α depend on the tumor-bearing 
host [12], especially its immune activating properties [13, 14] or destruction of the tumor 
vasculature [14, 15]. However, systemic use of TNF-α is limited through severe cytotoxic side 
effects leading to shock, tissue injury and even death, already observed at TNF-α levels 
which can endogenously be produced by the host [16]. To overcome limiting toxicities and 
locally enhancing therapeutic effects, multiple moieties (e.g. NGR, F8, L19, TCP-1) were 
already coupled to TNF-α, with the aim of guiding it to the specific domains present in the 
tumor vasculature [17-20]. For instance, TNF-α linked to the F8-moiety (F8-TNF) which 
targets the extra-domain A (EDA) of fibronectin was already demonstrated to have strong 
therapeutic efficacy against established subcutaneous (s.c.) soft tissue sarcomas [18]. 
Another means of increasing local drug concentrations to limit systemic side effects are 
intraarterial (i.a.) infusions. As already demonstrated in osteosarcoma patients, intratumoral 
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cisplatin concentrations are elevated if the drug was infused intraarterially compared to 
intravenous (i.v.) administrations [21]. In addition, we also demonstrated superior tumor 
control using an orthotopic osteosarcoma model when i.a. cisplatin was compared with i.v. 
cisplatin [22]. However, not only the efficacy of cisplatin but also the efficacy of other drugs 
might be increased through local, i.a. administration. 
In this study we investigated the potential of F8-TNF against osteosarcoma. Using a clinically 
relevant syngeneic K7M2L2 orthotopic mouse model of osteosarcoma, drug efficacy was first 
evaluated in the presence of a primary tumor and in dependence of its route of administration 
(i.e. i.a. versus i.v.). Next, drug efficacy against progressed osteosarcoma was assessed in 
an amputation model of osteosarcoma.  Especially the effects of F8-TNF (alone and 
combined with DOX) on the circulating tumor cells (CTCs), early and late pulmonary 
metastases as well as on cells of the immune system were investigated.  
  
3 Methods 
3.1 Generation of the K7M2L2 cell line 
Murine K7M2 osteosarcoma cells (CRL-2836) were kindly provided by Dr. Chand Khanna 
(Center for Cancer Research National Institute, Bethesda, MD, USA) and cultured in DMEM 
(4.5 g/l glucose)/HamF12 (1:1) medium (Invitrogen, Carlsbad, CA), supplemented with 10% 
heat-inactivated FCS (GIBCO, Basel, Switzerland), at 37°C in a humidified atmosphere 
containing 5% CO2. K7M2 cells were transduced with a lacZ reporter gene under control of a 
neomycin selection marker as described [23]. Ten µl of PBS/0.05% EDTA containing 1 x 105 
of K7M2/lacZ cells were injected into the left tibia (i.t.) of female, 8-10 week old BALB/c mice 
as described before [23]. The K7M2L2/lacZ cell line was obtained after two rounds of in vivo 
selection of pulmonary metastases-derived K7M2 cells according to Fidler’s method [24]. 
Briefly, around three weeks after intratibial (i.t.) injection of K7M2/lacZ cells, mice developed 
large primary tumors as well as pulmonary metastases. During sacrifice, the lungs of the 
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mice were collected and metastasized cells (K7M2L1/lacZ) were isolated by digestion of the 
lung tissue using collagenase B (Roche, Mannheim, Germany) and subsequently selected in 
cell culture medium containing 800 µg/ml G418 (Invitrogen, Life Technologies, Carlsbad, CA, 
USA). The resulting K7M2L1/lacZ cells were then reinjected (i.t.) into BALB/c mice in order to 
obtain K7M2L2/lacZ cells in the same manner. After in vivo selection, K7M2L2/lacZ cells 
were transduced with an mCherry-containing plasmid (pQCIXH, containing a hygromycin 
selection marker), which was kindly provided by Prof. Markus Rudin (Institute of Biomedical 
Engineering, University and ETH Zurich, Zurich, Switzerland). After transduction, 
K7M2L2/lacZ/mCherry cells were selected in tissue culture medium with 1 mg/ml of G418 
(Merck Millipore) and 400 µg/ml of hygromycin (Merck Millipore) to stably express lacZ and 
mCherry. A third round of transduction was performed using a pQCIXP plasmid containing 
the luciferase2 gene. The original plasmid was kindly provided by Dr. Geertje van der Horst 
(Leiden University, Leiden, The Netherlands). Ultimately, K7M2L2/lacZ/mCherry/luciferase2 
cells (referred to as “K7M2L2” throughout the manuscript) were selected using growth 
medium supplemented with 1 mg/ml of G418, 400 µg/ml of hygromycin and 1 µg/ml of 
puromycin (Invitrogen).  
3.2 K7M2L2 tumor inductions 
Female, 8-week-old BALB/c mice (BALB/cAnNCrl; Charles River Laboratories, Sulzfeld, 
Germany) were maintained as described [22]. K7M2L2 cells were cultured below confluence 
and 1 x 105 K7M2L2 cells were injected into left tibias as described [25]. Upon signs of 
limping due to the tumor burden, 0.1 mg/kg of intraperitoneal (i.p.) Buprenorphine (Temgesic; 
Reckitt Benckiser, Berkshire, UK) was given twice daily. Subcutaneous (s.c.) tumors were 
induced by injecting 1 x 106 K7M2L2 cells into the left flank of mice and experimental 
metastases were induced through i.v. injection of 1 x 106 K7M2L2 cells via the tail vein. Body 
weight measurements were performed weekly. Animal care and experimental procedures 
were in accordance with the institutional guidelines and approved by the Ethics Committee of 
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the Veterinary Department, Canton of Zurich, Switzerland (license numbers 64/2013 and 
160/2015).  
 
3.3 Tumor monitoring and bone measurements 
After xenografting, tumor growth in the hind limbs of the mice was monitored weekly using 
caliper measurements as described [26]. To determine tumor load in the lungs or detect 
remaining tumor cells at the site of amputation, luciferase activity was measured. Mice were 
anesthetized using 5% isoflurane (Forane; AbbVie, Inc., USA) and anesthesia was 
maintained with 2% isoflurane. XenoLight D-luciferin was injected via the mouse tail vein 
following the manufacturer’s instructions (PerkinElmer, Waltham, MA, USA). Subsequently, 
luciferase activity was measured in an IVIS Lumina XR (Caliper Life Sciences, Inc., 
Hopkinton, MA, USA) and quantified with Living Image v4.4 software (Xenogen Corporation, 
Alameda, CA, USA).  
Micro computed tomography (microCT) using a SkyScan1176 microCT system (Bruker, 
Billerica, MA, USA) was performed as described elsewhere [22]. Reconstituted images were 
segmented using CTAn v1.13.11.0 (Bruker, USA) to select regions of immature bone 
representing malignant bone formation. Immature bone volumes were determined in a region 
of interest starting from the distal end of the patella until the convergence of tibia and fibula. 
Volumes were calculated using the following formula: cortical bone volume = bone 
volumetumor-limb - bone volumehealthy-limb.  
3.4 Amputations 
Amputations were performed under 2% isoflurane anesthesia with pre-operative 0.1 mg/kg of 
i.p. Buprenorphine, adapting the procedure described by Wolfe et al. [27]. In brief, the hip 
region of the tumor bearing leg was shaved and disinfected with 70% ethanol. A 
circumferential skin incision was made with small scissors at the plane of the femur/ proximal 
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to the primary tumor. After isolating the femoral artery, vein and nerve (see procedure 
described in [22]), the femoral artery and vein were concurrently ligated with sterile silk 
sutures (Fine Science Tools GmbH, Heidelberg, Germany) and cut proximal of the caudal 
femoral artery. The circumferential musculature was transected distal to the level of vessel 
ligation and separated from the femur. Using saw-toothed scissors, the femur was then 
transected proximal to the knee joint, at a level which ensured complete macroscopic 
removal of the primary tumor. Next, the sciatic nerve was identified and transected, followed 
by the remainder of the ischiocrural musculature to create a flap for subsequent closure. The 
remaining musculature was used to cover the distal end of the transected femur using 7-0 
silk (Braun Melsungen, Melsungen, Germany). The skin was closed using 7-0 silk in an 
intermittent pattern. After surgery, the animals received i.p. 200 µl 0.9% NaCl to reestablish 
physiological fluid levels. Analgesia using 0.1 mg/kg of i.p. Buprenorphine was continued for 
48 hours and followed by carprofen (Rimadyl; Pfizer, New York, NY, USA; final 
concentration: 0.067 mg/ml in the drinking water) given ad libitum for 5 days [28].  
3.5 Determination of amount of circulating tumor cells and pulmonary metastases 
After completion of the experiment, whole mouse blood was obtained during necropsy via 
cardiac puncture. Three healthy, untreated female BALB/c mice served as negative controls. 
Red blood cell lysis was performed using ammonium-chloride-potassium (ACK) lysis buffer 
and the remaining cells were divided into two parts. One part was briefly centrifuged at 1250 
rpm for 3 min, dissolved in PBS and stored at -20°C for analysis of genomic DNA, while the 
second part was immediately analyzed using fluorescence-activated cell sorting (FACS). 
Genomic DNA was isolated using a QIAmp DNA blood Mini Kit (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions. Tumor-specific mCherry-DNA and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH)-DNA was amplified using quantitative PCR (input: 10 
ng of genomic DNA). Primers were purchased from Microsynth (Balgach, Switzerland) and 
used at 200 nM. Primer sequences are listed in Supplementary Table S1. For quantitative 
PCR, amplification reactions were carried out using Power SYBR Green PCR master mix 
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(Applied Biosystems, Foster City, CA, USA) and the StepOne Plus Real- Time PCR system 
(Applied Biosystems). Relative amounts of genomic mCherry were determined using the 2-
∆∆Ct method and normalized to the amount of murine GAPDH. 
FACS was performed to detect mCherry-positive (mCherry+) circulating tumor cells. 
Following red blood cell lysis of whole blood, cells were suspended in PBS containing 0.5% 
FCS (Gibco by Thermo Fisher Scientific, Waltham, MA, USA). Fluorescent mCherry+ cells 
were counted and normalized to the input volume of whole blood using a FACS Aria III 
cellsorter (BD Biosciences, San Jose, CA, USA). Post mortem, pulmonary metastases were 
counted as described [26].  
3.6 Experimental design 
In total, three mayor studies were performed: 1) “comparative treatment study”: to compare 
injections of i.v. and i.a. F8-TNF without amputation of the primary tumor after establishment 
of palpable tumors (n ≥ 8). In the “comparative treatment” study, the time for metastasis 
development was limited due to the rapid increase in morbidity of the animals following 
primary tumor growth. To specifically test the anti-metastatic effect of F8-TNF against 
established pulmonary metastases, we employed an amputation model of metastatic 
osteosarcoma in a “pilot amputation study”. 2) “pilot amputation study”: to determine the 
metastatic load after hind limb amputation at specific tumor volumes (no primary tumor (PT): 
n = 3; small PT: n = 6; medium PT: n = 8; large PT: n = 9). 3) “combination treatment study”: 
to determine the effect of F8-TNF alone or in combination with DOX on the growth of 
spontaneous pulmonary metastases and potential local recurrences  after amputation of the 
tumor-bearing hind limb (Group “vehicle”: n = 9; group “F8-TNF”: n = 9; group “DOX”: n = 8; 
group “Comb”(Combination; F8-TNF + DOX): n = 8). Mice that did not receive the planned 





3.7 Drug infusions 
F8-TNF was adjusted using PBS [18]. “Comparative treatment study”: Mice anesthetized with 
2% isoflurane were kept warm on a heating mat throughout the procedure. Intravenous 
infusions were performed via the tail vein using a 30G needle attached to a polyethylene 
catheter (Portex; Smiths Medical, Inc., USA) under control of a syringe pump (Legato; WPI, 
Inc., USA). Intraarterial infusions were performed similarly as described [22]. Mice received 
each treatment (PBS or 2 μg of F8-TNF) three times. Substances were administered every 
72 hours. In case of DOX, DOX (5 mg/kg, i.v.; Sandoz, Holzkirchen, Germany) treatment 
was administered only once, alone or prior to F8-TNF (2 μg per mouse,  i.v.). 
3.8 Immunohistology and immunofluorescence 
Following excision, primary tumors and lungs were embedded in Tissue-Tek® O.C.T. 
Compound (Sakura Finetek, USA), frozen on dry ice and cut (8-10 μm) in a CM3050S 
cryotome (Leica Biosystems, Newcastle, UK). Frozen tissue sections were fixed in ice-cold 
acetone, blocked using 20% FCS (Gibco by Thermo Fisher Scientific) in PBS and stained. 
Immunofluorescence was applied on frozen sections to detect EDA (biotinylated F8; 1:100; 
as described [18]), CD31 (anti-PECAM-1 rabbit polyclonal antibody, sc-1506-R, Santa Cruz 
Biotechnology, USA; 1:200), CD4+ cells (rat anti-CD4, BioXCell, West Lebanon, NH, USA; 
1:2000), CD8+ cells (rat anti-CD8a, BioXCell; 1:2000),  CD19+ B cells (rat anti-CD19, 
BioXCell; 1:1000) and natural killer (NK) cells (rabbit anti-asialo GM1, Wako Pure Chemical 
Industries, Osaka, Japan; 1:3000) using the respective primary antibodies /small 
immunoproteins (SIP) diluted in 0.2% BSA (Sigma-Aldrich, St. Louis, MO, USA). Primary 
immunoproteins were detected with streptavidin-coupled Cy-3 (Sigma-Aldrich), goat anti-
rabbit IgG-Alexa Fluor 647 (Life Technologies by Thermo Fisher Scientific), goat anti-rabbit 
IgG-Alexa Fluor 594 (Life Technologies) or goat anti-rat IgG-Alexa Fluor 594 (Life 
Technologies). Stained slides were mounted with fluorescent Shandon Immu-Mount (Thermo 
Fisher Scientific), images were taken with an Axio Observer Z1 (Zeiss, Oberkochen, 
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Germany) and analyzed using ImageJ v1.47 (U. S. National Institutes of Health, Bethesda, 
MD, USA).  
3.9 Human osteosarcoma samples and ethics statement 
The present study was approved by the local ethics committee (Ref. Nr. EK10/2007) and 
written informed consent was obtained from each subject or each subject's guardian. Primary 
human osteosarcoma tissue was stored at -80°C and embedded in Tissue-Tek® O.C.T. 
(Sakura) for sectioning and immunofluorescence.  
3.10 Statistical Analysis 
The results were given as mean ± standard error of the mean (SEM). Means of end point 
measurements were compared with one-way ANOVA or a Kruskal-Wallis test if the data was 
considered skewed (skewness >3). Means of time courses were compared by repeated two-
way ANOVA unless otherwise stated. In case of ANOVA, Bonferroni posttests were used to 
determine statistical differences between individual groups (indicated in graphs) whereas 
Dunn’s tests were used for skewed data. Dependent on the skewness of the data, Pearson 
or Spearman correlations were performed. All statistical tests were performed using Prism 5 
v5.01 software (GraphPad Software, Inc., La Jolla, CA, USA), were 2-sided and p<0.05 was 
regarded as statistically significant.   
 
4 Results 
4.1 EDA is expressed in human osteosarcoma tissue 
Immunofluorescence against EDA on various samples of primary human osteosarcoma 
demonstrated presence of EDA. Briefly, chemotherapy naïve osteosarcomas (“biopsy”; 5 of 6 
(83%); EDA+ specimens of total specimens (percentage)) showed more intense fluorescent 
staining of EDA compared with chemotherapy treated (“resection”; 5 of 5 (100%)) samples 
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(Fig. 1). Metastases present in lung (“LMet”; 2 of 2 (100%)) or bone metastases (“BMet”; 2 of 
2 (100%)) were all positive for EDA (Fig. 1).   
4.2 Comparative treatment study 
4.2.1 F8-TNF is well tolerated but lacks efficacy in primary tumors 
After confirming the presence of EDA in human osteosarcoma, the effects of F8-TNF against 
osteosarcoma were evaluated dependent on the route of administration (i.a. versus i.v.) 
using the K7M2L2 osteosarcoma model. Efficacy of F8-TNF was determined by measuring 
the primary tumor volume using caliper. After completing three treatments, no significant 
differences in primary tumor volumes were observed (Fig. 2A). TNF-α belongs to the class of 
osteoclastogenic cytokines [29]. To see if F8-TNF treatment might impact bone remodeling, 
the formation of immature bone during tumor growth was evaluated. An increase in tumor-
related immature bone production paralleling primary tumor volumes in the K7M2L2 model 
was observed (Pearson r = 0.43, P = 0.007). However, despite this correlation, and in line 
with the absence of changes in tumor growth, the immature bone produced by the tumors 
was not significantly affected by the F8-TNF treatment (Fig. 2B).  
Furthermore, body weights of the mice were recorded to see if the treatment itself impacts 
the general health of the mice. Throughout the study, no significant differences were 
observed among the different treatment groups (Supplementary Fig. 1A). However, due to 
the tumor growth, a continuous loss of body weight was observed. Since two different routes 
of drug administration were compared, blood perfusion of the tumor-bearing limb was 
monitored to identify whether surgery had influenced downstream blood flow. After three 
rounds of i.a. or i.v. infusions, no significant differences in perfusion of the region of primary 





4.2.2 Early metastatic growth is reduced by F8-TNF  
In contrast to the absence of effects of F8-TNF against the primary tumor, a reduction in 
systemic disease was observed after F8-TNF treatment. Interestingly, dependent on the size 
of the pulmonary metastases, metastases were differentially affected. Large metastases 
(diameter > 0.5 mm; Fig. 2C) or medium-sized metastases (diameter 0.5 - 0.1 mm; Fig. 2D) 
were less affected by the treatment while F8-TNF significantly reduced the number of 
micrometastases (diameter < 0.1 mm; Fig. 2E). To see if this reduction in metastatic cells is 
also linked to a treatment-dependent reduction of circulating tumor cells (CTCs), the amount 
of genomic mCherry DNA was determined analyzing the cellular fraction of blood samples. 
Treatment with F8-TNF showed a trend towards reduced numbers of CTCs (Fig. 2F).  The 
distribution pattern of the number of CTCs weakly correlated with the number of pulmonary 
micrometastases (Spearman r = 0.30, P = 0.127; data not shown). In addition to qPCR, the 
amount of CTCs after i.a. F8-TNF was determined using FACS in selected mice. Mice 
treated with i.a. F8-TNF had reduced numbers of mCherry+ tumor cells within the blood 
circulation (Supplementary Fig.S2).  
4.2.3 F8-TNF activates immune cells in the lung parenchyma 
Given the role of the immune system in controlling tumor progression, the numbers of 
various immune cells in the lung parenchyma were determined using immunofluorescence 
(Fig. 3A). Elevated numbers of CD4+ cells (Fig. 3B), CD8+ cells (Fig. 3C), and natural killer 
(NK) cells (Fig. 3D) were observed after F8-TNF treatment, irrespective of the route of drug 
administration.  
4.3 EDA is expressed in experimental osteosarcomas and human osteosarcoma 
To explain the differential efficacy of F8-TNF against the same cell line (metastases versus 
primary tumor), we investigated alterations in EDA-expression based on various 
microenvironments. Multiple K7M2L2-derived tumor tissues were analyzed using 
immunofluorescence (Fig. 4A). Although all experimental tumor samples were derived from 
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the same cell line, qualitative assessment showed only little expression or absence of EDA in 
intratibial primary tumors. In contrast, pulmonary metastases induced through i.v. injections 
or derived from a primary tumor were marked by high expression levels of EDA. Similarly, 
K7M2L2 cells s.c. injected yielded primary tumor volumes with increased levels of EDA 
compared with i.t. primary tumors. In line with the expression of EDA, s.c. primary tumors 
regressed (Fig. 4B) after F8-TNF treatment in contrast to intratibial (i.t.) primary tumors. 
Interestingly, varying expression levels and patterns of EDA (e.g. low versus high) were 
found between pulmonary metastases derived from the same K7M2L2 experimental primary 
tumor (data not shown). 
4.4 Pilot amputation study 
4.4.1 Large primary tumors are required for successful colonization of the lungs 
Primary tumors (PT) were amputated at different sizes (no PT: <25 mm3; small PT: 27-61 
mm3; medium PT: 102-250 mm3; large PT: 385-1500 mm3) and body weights as well as 
luciferase signals in the thoracic region were recorded. A significantly larger loss of body 
weights was detected in the group of large PT after amputation compared to the other groups 
(Fig. 5A). However, this difference disappeared three days later and no other differences in 
body weight loss were observed between the different groups. At the time of amputation, 
single tumor-bearing mice were sacrificed and the numbers of pulmonary metastases were 
determined. Large tumors correlated with higher numbers of pulmonary metastases (Fig. 
5B). In addition, luciferase signals were measured in the thoracic region to determine 
metastatic burden and different patterns of tumor progression were observed 
(Supplementary Table S2). For instance, the luciferase activity remaining at the site of 
amputation spontaneously disappeared, whereas the tumor burden in the lung of the same 
mouse increased (Fig. 5C, large PT). Furthermore, continuous thoracic luciferase activity 
above tissue background (> 106 p/s) was only observed when large PTs were amputated 
(Fig. 5D).  
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4.5 Combination treatment study 
4.5.1 F8-TNF does not prevent growth of established metastases 
Next, we tested the efficacy of F8-TNF against already established pulmonary metastases. 
DOX, a standard drug in osteosarcoma chemotherapy, was shown to improve the anti-tumor 
effect of F8-TNF even further [18]. Therefore, we combined the use of DOX and F8-TNF to 
evaluate the individual and combined efficacies against systemic disease. The number of 
CTCs was evaluated using FACS of mCherry+ tumor cells. However, no significant 
differences in mean numbers of CTCs were observed (Fig. 6A). Mice treated with vehicle 
(range: 0-34 mCherry+ cells / ml) or DOX (0-11) only, showed the highest maximum number 
of CTCs compared to F8-TNF (0-5) or comb (0-2) treated animals. 
Neither the absolute numbers of pulmonary metastases after sacrifice (Fig. 6B) nor the in 
vivo luciferase-activity measurements (Fig. 6C) detected significant differences between the 
various treatment groups. Nevertheless, a non-significant delay in growth of pulmonary 
metastases until the end of the treatment (= “9 d post treatment”) was observed with the 
combination treatment. All tested treatment regimens were well tolerated without causing a 
severe loss of body weight (Supplementary Fig. S3). Moreover, local soft tissue recurrences 
in the abdomen were detected in 33-38% of animals which have received limb amputation of 
a large primary tumor. However, no significant treatment-dependent differences in growth of 
local recurrences were observed (Supplementary Fig. S4).  
4.6 Spleen size is increased by F8-TNF treatment but numbers of CD4+ and CD8+ cells 
are not affected  
Enlarged spleens were observed in several immunocompetent mouse models of cancer and 
were associated with enhanced metastasis or increased granulocytosis [30-32]. Speculating 
that F8-TNF treatment would also influence the composition of lymphocytes or granulocytes 
in our osteosarcoma model, the lengths of spleens were measured. Significantly enlarged 
spleens were observed after F8-TNF treatment compared with vehicle- or DOX-treated mice 
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(Fig. 6A). The mean length of spleens of comb-treated mice was shorter than spleens of F8-
TNF treated mice, without reaching significance. Similar to the “comparative treatment” 
study, we again investigated the immune infiltrate of the lungs. However, no significant 
differences among numbers of CD4+ (Fig. 6B) or CD8+ cells (Fig. 6C) in the lung 
parenchyma were identified. 
 
5 Discussion 
In this study, we studied the effects of targeted TNF-α in early and late stages of 
osteosarcoma biology. Here, we showed that F8-TNF targeted pulmonary metastases of 
osteosarcoma and reduced establishment of early-stage micrometastases, but was not able 
to significantly delay growth of already established pulmonary metastases. In addition, we 
could show that the route of administration (i.a. versus i.v.) of F8-TNF had no impact on drug 
efficacy, suggesting a targeting effect that is independent of temporary high local drug 
concentrations.  
This study and others demonstrated the presence of EDA in primary human osteosarcoma 
tissues, rendering it a valid target for future therapeutic approaches against osteosarcoma 
[33]. However, our results demonstrated a differential expression of EDA in the K7M2L2 
osteosarcoma model, with no expression in orthotopic primary tumors, whereas pulmonary 
metastases within the same animal expressed EDA strongly. As demonstrated by others, an 
osteoblast cell line and cells involved in human bone remodeling after a fracture strongly 
expressed EDA [34]. Thus, it is possible that disturbance due to i.t. injections in a bony 
microenvironment already induced expression of EDA, so that mostly EDA-negative primary 
i.t. tumors develop. To further investigate this observation, the same osteosarcoma cells 
were transplanted s.c. and mice were treated with F8-TNF. Not only EDA expression in 
subcutaneous tumors was observed but also strong anti-tumor effects of F8-TNF against s.c. 
K7M2L2 transplants were observed, supporting the results of Mortara et al. [35]. Moreover, 
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early lung tumors displayed a patchy expression of EDA in contrast to late lung tumors, 
where a vascular expression pattern of EDA was observed [36]. In line with these results, our 
study also demonstrated dynamic expression patterns of EDA in pulmonary metastases, 
ranging from patchy expression in early metastases to a patchy expression surrounding the 
pulmonary nodule while central EDA was mostly associated with the blood vessels. In 
summary, these results may indicate that the expression of EDA depends on the 
microenvironment and the developmental stage of the tumor. Therefore, the timing of 
administration of EDA-targeted chemokines should be considered in future efficacy studies.  
It is already widely accepted that establishment of metastasis is a highly selective process. 
Thus, only a specific set of specialized tumor cells is capable of intravasation and distant 
organ colonization [37]. With respect to osteosarcoma, relatively little is known about CTCs, 
due to a lack of established markers. Nevertheless, it is known from other types of cancer, 
for instance breast cancer, that natural CTCs established metastases of a defined 
metastasis-related gene expression pattern that differed from the pattern derived from 
metastases established through systemic injection of tumor cells [38]. Especially expression 
of immunomodulatory molecules, such as the immune evasion signal CD47, might determine 
the success of CTCs to establish metastases in an immunocompetent host [39, 40]. In order 
to study the efficacy of an immunomodulatory drug such as F8-TNF, a model recapitulating 
the establishment of naturally- / immune-selected pulmonary metastases is required. The 
here presented study used an immunocompetent K7M2-derived model system which was 
already shown to properly mimic the different stages of human osteosarcoma progression 
(i.e. CTCs, development of pulmonary metastases) while at the same time permitting the use 
of basic osteosarcoma therapy (e.g. removal of the primary tumor), hence, it was considered 
clinically relevant [41].  
In a first study, a reduction of micrometastatic disease and thus, preventive action of F8-TNF 
against seeding of pulmonary metastases was demonstrated. Previously, other studies 
demonstrated altered levels of immune cells which were linked to success of therapy against 
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osteosarcoma. For instance, an increase in CD8+ T cells [42] or increases in NK cells [43, 
44] seem to be mediators of successful immunotherapy against osteosarcoma and its 
metastases. Likewise, our study demonstrated an increase in CD4+, CD8+ and NK cells in 
the lung parenchyma after F8-TNF treatment, which may provide an explanation for the 
reduced numbers of early pulmonary metastases. Especially early intraluminal metastatic 
seeds might be eliminated by an increase of NK cells in the lung parenchyma [45]. 
To study late metastatic disease, a model was required that allowed longer study times of 
pulmonary metastases. Due to ethical reasons, the presence of a too large primary tumor is 
considered as a drop-out criterion. Consequently, an amputation model not only provided 
longer study times of pulmonary metastases but was also a better representation of clinical 
late metastatic osteosarcoma, where the primary tumor was most frequently removed. Thus, 
the use of a model of spontaneous metastases is desired to fully demonstrate a drug’s 
therapeutic value against late metastases [46]. Using such a model representing late stage 
osteosarcoma, we demonstrated that overt pulmonary metastases were not affected by TNF-
F8 treatment. Even the addition of DOX to F8-TNF only slightly delayed further growth of 
established metastases. Interestingly, enlarged spleens were observed after F8-TNF 
therapy, yet only in the case of late metastatic disease. As demonstrated by others using 
fibrosarcoma or breast cancer models, enlarged spleens were correlated with increased 
numbers of MDSC [47] or neutrophils [48], respectively, both of which are indicative for an 
immunosuppressive environment [49]. These observations may suggest the presence or the 
adaptation of mechanisms helping metastasized tumor cells to successfully evade the 
immune system, which should be subject of further investigations. 
This study showed that targeting of pulmonary metastasis using F8-TNF in osteosarcoma is 
feasible to control early stage metastasis, yet not sufficient to eradicate already established 
pulmonary metastases. Future studies should investigate the precise mechanisms of 
improved micrometastatic control of F8-TNF treatment. In addition, not only novel immune-
targeted drugs influence the immune system but also chemotherapeutics used against 
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osteosarcoma affect cells of the immune system in many ways. For instance, multidrug 
chemotherapy can cause neutropenia [50], DOX can induce immunogenic cell death [9] and 
cisplatin can either increase or reduce the number of lymphocyte numbers dependent on its 
concentration [51]. Thus, future studies might also evaluate combinatorial treatments of F8-
TNF together with conventional multidrug chemotherapy to identify optimal treatment 
schemes.  
In conclusion, the present study demonstrated efficacy of F8-TNF against early metastatic 
disease irrespective of the route of administration. However, treatment with F8-TNF in 
combination with DOX had no significant inhibitory effect on late metastatic disease in a 
clinically relevant model of progressed osteosarcoma.  
6 Acknowledgments 
We would like to thank Philipp Probst and Teresa Hemmerle for their technical and 
administrative support.   
7 List of abbreviations: 
ACK: ammonium-chloride-potassium 
BMet: bone metastasis 
CTCs: circulating tumor cells 
DOX: doxorubicin 
EDA: extra-domain A 
FACS: fluorescence-activated cell sorting 
F8-TNF: EDA-targeted tumor necrosis factor alpha 






LMet: lung metastasis 
MDSC: myeloid-derived suppressor cell 
PT: primary tumor 
qPCR: quantitative polymerase chain reaction 
s.c.: subcutaneous  
SIP: small immuno-protein 
TCI: tumor cell injection 
TNF-α: tumor necrosis factor alpha 
8 Ethics approval: 
Animal care and experimental procedures were in accordance with the institutional 
guidelines and approved by the Ethics Committee of the Veterinary Department, Canton of 
Zurich, Switzerland (Licenses number 64/2013 and 160/2015). The patient samples were 
obtained after written informed consent and approval by the local ethics committee (Ref. Nr. 
EK10/2007). 
9 Authors' Contributions: 
Conceptualization: B. Robl, S.M. Botter, A. Boro, D. Neri, B. Fuchs 
Methodology: B. Robl, B. Fuchs 
Investigation: B. Robl, S.M. Botter, A. Boro, D. Meier 
Project administration: B. Robl, A. Boro, S.M. Botter 
106 
 
Writing - original draft preparation: B. Robl 
Writing - review and editing: S.M. Botter, D. Neri, B. Fuchs  
Resources: D. Neri, B. Fuchs 
Supervision: S.M. Botter, D. Neri, B. Fuchs  
10 Titles and legends to figures 
Figure 1. EDA is expressed in various human osteosarcoma tissues. Represantative 
examples of EDA expression in a biopsy (before chemotherapy), resection (after 
chemotherapy), bone metastasis (BMet) and lung metastasis (Lmet). 200X original 
magnification. Nuclei were counterstained with Hoechst (blue). All scale bars correspond to 
100 µm. 
Figure 2. F8-TNF (i.v. and i.a.) has no inhibitory effect on K7M2L2 primary tumor growth yet 
reduces numbers of small pulmonary metastases. (A) Tumor volumes determined by caliper 
(n ≥ 8; repeated measures two-way ANOVA). Days of drug infusion are indicated by black 
arrow heads. (B) Immature bone volumes as determined by microCT scans before and after 
treatment (n ≥ 8; repeated measures two-way ANOVA). Volumes of immature bone were 
analyzed both in control limbs and in tumor-bearing limbs. b: before treatment; a: after 
treatment; CtrL: control limb; TuL: tumor-bearing limb. Total number of superficial pulmonary 
metastases with (C) a diameter > 0.5 mm, (D) a diameter of 0.1 - 0.5 mm or (E) a diameter < 
0.1 mm, determined after X-gal staining (n ≥ 5). (F) Genomic mCherry normalized by GAPDH 
was analyzed using whole blood samples. Highest amount of mCherry was set as 100% and 
relative values are shown (n ≥ 6).  
Figure 3. Treatment with F8-TNF increases infiltration of immune cells in the lung. (A) 
Representative examples of immunofluorescence analysis of CD4+ T cells in the lung after 
each treatment (from top: i.v. vehicle; i.v. F8-TNF; i.a. vehicle; i.a. F8-TNF). Total numbers of 
107 
 
CD4+ ((B), n ≥ 4), CD8+ ((C), n ≥ 4) and NK cells ((D), n ≥ 3) determined in five high power 
fields (HPF) from lungs of individual mice. *p<0.05; **p<0.01; ***p<0.001. 
Figure 4. EDA is expressed differently depending on the site of tumor growth. (A) 
Representative sections demonstrate site-dependent EDA (red) expression of K7M2L2 
osteosarcoma cells. Intratibial primary tumor (i.t. PT): 100X original magnification; s.c. PT: 
100X; intravenously injected lung metastasis (i.v. LMet): 100X; spontaneous LMet: 200X. All 
scale bars correspond to 100 µm. (B) Tumor volumes determined by caliper during F8-TNF 
treatment (n = 1-2). 
Figure 5. Characterization of the osteosarcoma amputation model. (A) Changes in body 
weight prior to and after the amputation are indicated (n ≥ 3; repeated measures two-way 
ANOVA, **p<0.01). On the day of amputation (black arrow), body weights were measured 
before the amputation (d 29) and immediately after removal of the tumor-bearing limb (d 
29.5). (B) Correlation between increasing primary tumor volume and metastases (n = 3; 
Pearson correlation). (C) Representative example of metastatic dynamics after amputation 
observed in the same mouse. After amputation, remaining tumor cells (black arrowhead) 
could disappear spontaneously (black arrowhead) or continue growing (not shown).  i: 2 
weeks (w) prior to amputation; ii: 10 min post amputation; iii: 1 month post amputation. (D) 
Development of luciferase activity in the lungs dependent on the size of the amputated PT (n 
= 3-9; repeated measures two-way ANOVA). 
Figure 6. F8-TNF and DOX do not inhibit late stage metastatic osteosarcoma or affect 
lymphocytes in the lung. (A) CTCs analyzed using fluorescence-activated cell sorting of 
mCherry+ tumor cells detected in whole blood (n ≥ 8). (B) Quantification of lacZ+ 
osteosarcoma cells detected on the surface of the small lobe of the lung after X-gal staining 
postmortem (n ≥ 8). (C) Continuous in vivo monitoring of luciferase+ tumor cells in the 
thoracic region by measuring luminescent flux (n ≥ 8). Black arrowheads indicate 
administration of treatment. d: days. (D) Lengths of spleens were measured ex vivo after 
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sacrifice of the mice (n ≥ 8). Numbers of (E) CD4+ and (F) CD8+ cells in the lungs 
determined in five high power fields (HPF) from lungs of individual mice (n = 6). 
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Supplementary Table S1. Primer sequences 














Supplementary Table S2. Development of pulmonary metastases and recurrences in dependence of 
tumor volume at amputation 





at amputation site 




after 2 months Total  
No detectable PT 0 (0) 0 (0) 0 (0) 0 (0) 3 
Small PT 2 (22) 0 (0) 0 (0) 0 (0) 6 
Medium PT 0 (0) 0 (0) 0 (0) 0 (0) 6 



















































12 Supplementary methods  
Tumor perfusion measurements 
To monitor tumor perfusion, laser speckle contrast imaging of the hind limbs was conducted 
using a moorFLPI Full-Field Perfusion Imager (Moor instruments Ltd., Devon, UK). Flux-
ratios (flux-ratio= Fluxtumor-bearing limb / Fluxcontralateral limb, similar to as described by Robl et al.. 
Robl B, Botter SM, Pellegrini G, Neklyudova O, Fuchs B. Evaluation of intraarterial and 
intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an 
orthotopic xenograft mouse model. J Exp Clin Cancer Res. 2016;35(1):113. Epub 




8 Conclusion and Outlook 
Despite advances in multi-modal treatment, survival rates of metastatic osteosarcoma 
patients remain at a low 20-30% since the start of the clinical documentations of 
osteosarcoma. Nevertheless, surgery combined with multidrug chemotherapy increased 
survival rates of patients with localized disease to 60%, yet remained at this level for almost 
four decades. These numbers clearly highlight the need for improved treatment strategies for 
a rare disease such as osteosarcoma. Hence, a better understanding of the disease at many 
stages is required to improve osteosarcoma therapy. To achieve this goal, sophisticated 
preclinical models as well as analysis of clinical samples are required in order to better 
understand the influence of modern chemotherapy against osteosarcoma.  
Until now, mostly untreated (naïve) patient material is used for the investigation of putative 
biomarkers for osteosarcoma under the valid presumption that chemotherapy influences the 
protein expression pattern of tumor cells. Thus, a biomarker detected in untreated tissue 
might have a different prognostic value if the same biomarker is studied in already treated 
tissue. Our results demonstrated that the use of chemotherapy-treated material, which is 
available at larger quantities compared with biopsied material, is feasible under certain 
conditions (e.g. analysis of tissue derived from grade 2 to grade 6 responders) for studying 
molecular markers in primary human osteosarcoma tissue. Surprisingly, the presence of 
cytP16 correlated with a poor response and poor prognosis if treated osteosarcoma samples 
were studied. This is contrasting with the prognostic value of nuclear p16 being indicative for 
improved survival if studied in untreated chemotherapy-naïve tissue. Likely, chemotherapy 
altered osteosarcoma cells by inducing a dysregulation of the p16 protein, changing its 
prognostic value. Given the altered subcellular localization of p16 after chemotherapy, the 
protein itself (238), the function of nuclear-cytoplasmic shuttling (240) or the structure of the 
nuclear pore complex (243) might be altered in surviving tumor cells after multidrug 
chemotherapy. Nevertheless, further studies are required to more completely decipher the 
role of cytP16 in the resistance mechanisms of osteosarcoma cells against multidrug 
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chemotherapy. Our studies provide a basis for future studies to specifically study resistance 
mechanisms of osteosarcoma against standard chemotherapy, for instance through 
mechanistic studies using the herein described cytP16+ osteosarcoma cell lines. It will be 
interesting to see, if the occurrence of cytP16 in these cell lines has a common origin. 
Studying of potential findings in treated primary osteosarcoma tissues might confer clinical 
relevance as well as provide a rational for further testing of additives to standard 
chemotherapy. Ultimately, the so gained knowledge could improve combination therapies 
through specific tailoring of standard chemotherapy to counteract developing mechanisms of 
resistance.  
Another means of potentially improving current chemotherapy is the local administration of 
chemotherapy. Here presented results demonstrated a clear advantage of i.a. CDDP in 
terms of tumor control compared with equivalent concentrations of i.v. CDDP. Similar to 
CDDP, other small molecules used in anti-cancer therapy could achieve a much larger effect 
with respect to tumor control if administered via the tumor feeding artery compared with 
systemic administration. Our study demonstrated a user-friendly i.a. approach that could 
economically be used by many other researchers conducting mouse studies. Using i.a. 
infusions, much higher local doses could be achieved without compromising systemic drug 
concentrations. Despite the advantages of i.a. access in osteosarcomas of the extremities, 
future studies might also evaluate i.a. drug administrations against other solid cancers with 
relatively easy access to a tumor-feeding artery. Even in the case of targeted therapy (i.e. 
small molecule inhibitors against a specific target), i.a. infusions might achieve a more 
complete perfusion of poorly vascularized regions of a tumor and thus, might reduce the 
frequency of drug resistances occurring in those regions. Especially anti-angiogenic small 
molecules such as pazopanib or sunitinib might be interesting candidates for i.a. 
administration. First, similar to cytotoxic chemotherapy, systemic administration of sunitinib is 
limited by severe side effects (244). Secondly, tumor control by i.a. CDDP in our study was, 
at least partially, achieved through anti-angiogenic effects. Future therapy studies might 
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evaluate small molecular drugs in a route-dependent manner to optimally titrate the dose to 
be received by the tumor while optimally sparing sensitive healthy tissues, similar to 
approaches used in radiotherapy. Finally, more effective first-line therapy against the primary 
tumor might also decrease the development of metastases. Thus, we emphasize the 
evaluation of i.a. administrations of novel as well as already known drugs against solid 
cancers using a similar preclinical model system as presented in course of this work. 
Nevertheless, before clinical use of i.a. chemotherapy against osteosarcoma might be 
appealing again, a future preclinical study should evaluate the efficacy of i.a. administration 
of the already used multidrug regimen (i.e. MAP) and compare it to i.v. administrations in a 
clinically relevant experimental model. Especially the evaluation of the long term effects such 
as development and growth of metastases or survival of the model animals in dependence of 
the route of standard chemotherapy administration will be important. The model systems 
described in this work fulfill these criteria and therefore lay a foundation for future preclinical 
studies assessing the administration of various combined chemotherapy protocols against 
osteosarcoma in a route-dependent manner.  
In osteosarcoma, pulmonary metastases are still the most common cause of disease-related 
death. Therefore, a potential increase in osteosarcoma patient survival implies the effective 
treatment of systemic spread and metastatic disease. Due to the fact that surgical removal of 
metastases is limited by the used detection methods and the concomitant removal of vital 
tissues, alternative metastases-targeted approaches are required. At best, eradication of 
systemic disease is achieved through a metastasis-targeted activation of the immune system 
and the generation of immune memory to avoid regrowth of systemic cancer. To this end, a 
novel immunostimulatory compound (F8-TNF) as targeted treatment against pulmonary 
metastases was evaluated. Despite efficacy against early pulmonary metastases, F8-TNF 
did not reduce the growth of late, established pulmonary metastases. Thus, our results ask 
for a more appropriate or more efficacious treatment. However, combination with 
immunostimulatory DOX (245) only slightly improved therapeutic efficacy of F8-TNF against 
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established metastatic disease. The fact that both drugs are activators of the immune 
system, suggest the presence of an immunosuppressive environment being created by late 
pulmonary metastases. Although our results support the use of other cytokines than TNF-α 
to be used against metastatic osteosarcoma, the principle of guiding cytokines using an 
EDA-targeting moiety (i.e. F8) to pulmonary metastases might still be successfully applied 
against osteosarcoma as demonstrated by the presence of EDA in various human tissue 
specimens. Therefore, subsequent studies might evaluate other EDA-targeted cytokines and 
drug combinations against metastatic osteosarcoma. A promising approach could be the 
combination of an EDA-targeted immunostimulatory cytokine with immune blockade 
inhibitors (e.g. ipilimumab or anti-PD1/PDL1 antibodies) to guide therapy towards established 
metastatic disease. Anti-osteoclastogenic cytokines such as IFN-γ and IL-13 or a potent 
stimulator of NK cells such as IL-2 might also be more appropriate than pro-osteoclastogenic 
TNF-α in treating osteogenic pulmonary metastases (246), considering the interdependence 
between osteosarcoma, immune cells and osteoclast development.  
In conclusion, the current successful multi-modal treatment approach as well as new 
therapeutic approaches of osteosarcoma therapy should be studied using proper preclinical 
models supported by the use of clinical osteosarcoma specimens in order to improve survival 
rates of patients with metastatic osteosarcoma. Using the here presented preclinical toolbox 
(i.e. i.v. versus i.a., surgical removal of the primary tumor, targeted cytokines, standard 
chemotherapeutics, in vivo monitoring of metastatic disease), a multitude of combinatorial 
treatment regimens can already be evaluated in a preclinical yet clinically relevant setting to 
precisely study the mechanisms of action of various drug candidates. A more complete 
understanding of the cell of origin of osteosarcoma as well as the precise roles of cytokines 
and cells of the immune system on cells of osteoid lineage will be required to successfully 
treat metastatic osteosarcomas. Once a more complete understanding of the effects on the 
immune system of common chemotherapeutics against osteosarcoma is achieved, a 
multimodal approach consisting of chemotherapy and surgery together with (targeted) 
130 
 





1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates 
from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results 
Program. Cancer. 2009;115:1531-43. 
2. Christine Bouchardy J-ML, Claudia Kühni. Krebs in der Schweiz - Stand und 
Entwicklung von 1983 bis 2007.  Statistik der Schweiz. Neuchâtel: Bundesamt für 
Statistik (BFS), National Institute for Cancer Epidemiology and Registration (NICER), 
Schweizer Kinderkrebsregister (SKKR); 2011. 
3. Howlader N NA, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, 
Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin 
KA. SEER Cancer Statistics Review, 1975-2010. November 2012 ed: National 
Cancer Institute. Bethesda, MD; 2012. 
4. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, et al. 
A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. 
2012;2012:704872. 
5. Cotterill SJ, Wright CM, Pearce MS, Craft AW. Stature of young people with 
malignant bone tumors. Pediatr Blood Cancer. 2004;42:59-63. 
6. Seton M. Paget disease of bone: diagnosis and drug therapy. Cleve Clin J 
Med. 2013;80:452-62. 
7. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. 
Journal of bone and mineral research : the official journal of the American Society for 
Bone and Mineral Research. 2006;21 Suppl 2:P58-63. 
8. Savage SA, Mirabello L. Using epidemiology and genomics to understand 
osteosarcoma etiology. Sarcoma. 2011;2011:548151. 
9. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone 
osteosarcoma in the pediatric age: state of the art. Cancer treatment reviews. 
2006;32:423-36. 
10. Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, et al. Grade of 
chemotherapy-induced necrosis as a predictor of local and systemic control in 881 
patients with non-metastatic osteosarcoma of the extremities treated with 
neoadjuvant chemotherapy in a single institution. European journal of cancer. 
2005;41:2079-85. 
11. Ragland BD, Bell WC, Lopez RR, Siegal GP. Cytogenetics and molecular 
biology of osteosarcoma. Lab Invest. 2002;82:365-73. 
12. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances 
for pediatric osteosarcoma. Oncologist. 2004;9:422-41. 
13. Ritter J, Bielack SS. Osteosarcoma. Annals of oncology : official journal of the 
European Society for Medical Oncology / ESMO. 2010;21 Suppl 7:vii320-5. 
14. Aisen AM, Martel W, Braunstein EM, McMillin KI, Phillips WA, Kling TF. MRI 
and CT evaluation of primary bone and soft-tissue tumors. AJR Am J Roentgenol. 
1986;146:749-56. 
15. Donohoe KJ, Henkin RE, Royal HD, Brown ML, Collier BD, O'Mara RE, et al. 
Procedure guideline for bone scintigraphy: 1.0. Society of Nuclear Medicine. Journal 
of nuclear medicine : official publication, Society of Nuclear Medicine. 1996;37:1903-
6. 
16. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone 
metastases. Q J Nucl Med. 2001;45:53-64. 
132 
 
17. Byun BH, Kong CB, Lim I, Kim BI, Choi CW, Song WS, et al. Comparison of 
(18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone 
metastasis in osteosarcoma. Skeletal Radiol. 2013;42:1673-81. 
18. Liu F, Zhang Q, Zhu D, Li Z, Li J, Wang B, et al. Performance of Positron 
Emission Tomography and Positron Emission Tomography/Computed Tomography 
Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence 
Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis. Medicine 
(Baltimore). 2015;94:e1462. 
19. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, et al. 
Primary metastatic osteosarcoma: presentation and outcome of patients treated on 
neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 
2003;21:2011-8. 
20. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment 
and follow-up. Annals of oncology : official journal of the European Society for 
Medical Oncology / ESMO. 2014;25 Suppl 3:iii113-23. 
21. Bertoni F, Bacchini P, Staals EL, Davidovitz P. Dedifferentiated parosteal 
osteosarcoma: the experience of the Rizzoli Institute. Cancer. 2005;103:2373-82. 
22. D'Andrea K, Dreyer J, Fahim DK. Utility of Preoperative Magnetic Resonance 
Imaging Coregistered with Intraoperative Computed Tomographic Scan for the 
Resection of Complex Tumors of the Spine. World Neurosurg. 2015;84:1804-15. 
23. Yedururi S, Morani AC, Gladish GW, Vallabhaneni S, Anderson PM, Hughes 
D, et al. Cardiovascular involvement by osteosarcoma: an analysis of 20 patients. 
Pediatr Radiol. 2016;46:21-33. 
24. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of 
musculoskeletal sarcoma. Clinical orthopaedics and related research. 1980:106-20. 
25. Stacy GS, Mahal RS, Peabody TD. Staging of bone tumors: a review with 
illustrative examples. AJR Am J Roentgenol. 2006;186:967-76. 
26. Vasquez L, Tarrillo F, Oscanoa M, Maza I, Geronimo J, Paredes G, et al. 
Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in 
Children: A 15-Year Single-Institution Experience. Front Oncol. 2016;6:22. 
27. Nataraj V, Rastogi S, Khan SA, Sharma MC, Agarwala S, Vishnubhatla S, et 
al. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy 
protocol without high dose methotrexate and delayed metastasectomy: a single 
center experience of 102 patients. Clin Transl Oncol. 2016. 
28. Rasalkar DD, Chu WC, Lee V, Paunipagar BK, Cheng FW, Li CK. Pulmonary 
metastases in children with osteosarcoma: characteristics and impact on patient 
survival. Pediatr Radiol. 2011;41:227-36. 
29. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The 
effect of adjuvant chemotherapy on relapse-free survival in patients with 
osteosarcoma of the extremity. N Engl J Med. 1986;314:1600-6. 
30. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC. Does the 
histological subtype of high-grade central osteosarcoma influence the response to 
treatment with chemotherapy and does it affect overall survival? A study on 570 
patients of two consecutive trials of the European Osteosarcoma Intergroup. 
European journal of cancer. 2002;38:1218-25. 
31. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. 
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis 
of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group 
protocols. J Clin Oncol. 2002;20:776-90. 
32. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, et al. 
Predictive factors of disease-free survival for non-metastatic osteosarcoma of the 
133 
 
extremity: an analysis of 300 patients treated at the Rizzoli Institute. Annals of 
oncology : official journal of the European Society for Medical Oncology / ESMO. 
2001;12:1145-50. 
33. Yong B, Tan P, Yin J, Zou C, Xie X, Wang J, et al. Suboptimal chemotherapy 
is an adverse prognostic factor in osteosarcoma. World J Surg Oncol. 2012;10:191. 
34. Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Post operative infection 
and increased survival in osteosarcoma patients: are they associated? Ann Surg 
Oncol. 2007;14:2887-95. 
35. McTiernan A, Jinks RC, Sydes MR, Uscinska B, Hook JM, van Glabbeke M, et 
al. Presence of chemotherapy-induced toxicity predicts improved survival in patients 
with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report 
from the European Osteosarcoma Intergroup. Eur J Cancer. 2012;48:703-12. 
36. Chen YU, Xu SF, Xu M, Yu XC. Postoperative infection and survival in 
osteosarcoma patients: Reconsideration of immunotherapy for osteosarcoma. Mol 
Clin Oncol. 2015;3:495-500. 
37. Moore C, Eslin D, Levy A, Roberson J, Giusti V, Sutphin R. Prognostic 
significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood 
Cancer. 2010;55:1096-102. 
38. Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, 
Rodrigo JP, et al. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted 
Therapies. Stem Cells Int. 2016;2016:3631764. 
39. Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem 
cells or osteoblast committed cells? Bone. 2014;62:56-63. 
40. Rubio R, Abarrategi A, Garcia-Castro J, Martinez-Cruzado L, Suarez C, Tornin 
J, et al. Bone environment is essential for osteosarcoma development from 
transformed mesenchymal stem cells. Stem Cells. 2014;32:1136-48. 
41. Kuijjer ML, Hogendoorn PC, Cleton-Jansen AM. Genome-wide analyses on 
high-grade osteosarcoma: making sense of a genomically most unstable tumor. 
International journal of cancer. 2013;133:2512-21. 
42. Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, et 
al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated 
osteolysis. Biochimica et biophysica acta. 2004;1704:49-57. 
43. Orr FW, Lee J, Duivenvoorden WC, Singh G. Pathophysiologic interactions in 
skeletal metastasis. Cancer. 2000;88:2912-8. 
44. Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast 
cancer bone metastases. Clinical orthopaedics and related research. 2003:S32-8. 
45. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth 
factors in bone matrix. Isolation of multiple types by affinity chromatography on 
heparin-Sepharose. J Biol Chem. 1986;261:12665-74. 
46. Lamora A, Talbot J, Bougras G, Amiaud J, Leduc M, Chesneau J, et al. 
Overexpression of smad7 blocks primary tumor growth and lung metastasis 
development in osteosarcoma. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2014;20:5097-112. 
47. Bridge JA, Nelson M, McComb E, McGuire MH, Rosenthal H, Vergara G, et al. 
Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. 
Cancer Genet Cytogenet. 1997;95:74-87. 
48. Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, et 
al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic 
hybridization. Cancer research. 1995;55:1334-8. 
49. Egas-Bejar D, Anderson PM, Agarwal R, Corrales-Medina F, Devarajan E, 
Huh WW, et al. Theranostic Profiling for Actionable Aberrations in Advanced High 
134 
 
Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The 
Human Fingerprint Hypothesis. Oncoscience. 2014;1:167-79. 
50. Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, et al. Recurrent 
somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. 
Cell Rep. 2014;7:104-12. 
51. Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, et al. 
Complementary genomic approaches highlight the PI3K/mTOR pathway as a 
common vulnerability in osteosarcoma. Proceedings of the National Academy of 
Sciences of the United States of America. 2014;111:E5564-73. 
52. Jones KB. Transposon mutagenesis disentangles osteosarcoma genetic 
drivers. Nat Genet. 2015;47:564-5. 
53. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. 
The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional 
activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 
1993;13:7393-8. 
54. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, et al. 
Identification of osteosarcoma driver genes by integrative analysis of copy number 
and gene expression data. Genes Chromosomes Cancer. 2012;51:696-706. 
55. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. 
Massive genomic rearrangement acquired in a single catastrophic event during 
cancer development. Cell. 2011;144:27-40. 
56. Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, et al. 
Genomic alterations and allelic imbalances are strong prognostic predictors in 
osteosarcoma. Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2010;16:4256-67. 
57. Kuijjer ML, Namlos HM, Hauben EI, Machado I, Kresse SH, Serra M, et al. 
mRNA expression profiles of primary high-grade central osteosarcoma are preserved 
in cell lines and xenografts. BMC Med Genomics. 2011;4:66. 
58. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, et 
al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer 
research. 1994;54:3042-8. 
59. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of 
the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic 
implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 
2000;120:91-8. 
60. Mohseny AB, Tieken C, van der Velden PA, Szuhai K, de Andrea C, 
Hogendoorn PC, et al. Small deletions but not methylation underlie CDKN2A/p16 
loss of expression in conventional osteosarcoma. Genes Chromosomes Cancer. 
2010;49:1095-103. 
61. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, et al. Copy number gains 
in EGFR and copy number losses in PTEN are common events in osteosarcoma 
tumors. Cancer. 2008;113:1453-61. 
62. Duhamel LA, Ye H, Halai D, Idowu BD, Presneau N, Tirabosco R, et al. 
Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) 
amplification in parosteal and conventional osteosarcoma subtypes. Histopathology. 
2012;60:357-9. 
63. Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, et al. Genetic amplification 
of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, 
in human osteosarcoma. Cancer. 2011;117:4925-38. 
135 
 
64. Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, et al. Oncogene 
alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem. 
1996;63:37-50. 
65. Papachristou DJ, Batistatou A, Sykiotis GP, Varakis I, Papavassiliou AG. 
Activation of the JNK-AP-1 signal transduction pathway is associated with 
pathogenesis and progression of human osteosarcomas. Bone. 2003;32:364-71. 
66. Weekes D, Kashima TG, Zandueta C, Perurena N, Thomas DP, Sunters A, et 
al. Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1. 
Oncogene. 2015. 
67. Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, et al. Loss of imprinting of 
IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of 
a CTCF-binding site. Hum Mol Genet. 2003;12:535-49. 
68. Zhang XH, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, et al. Selection of bone 
metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell. 
2013;154:1060-73. 
69. Kaji H, Sugimoto T, Kanatani M, Nishiyama K, Nasu M, Chihara K. Insulin-like 
growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid 
hormone. J Cell Physiol. 1997;172:55-62. 
70. Sadikovic B, Yoshimoto M, Chilton-MacNeill S, Thorner P, Squire JA, 
Zielenska M. Identification of interactive networks of gene expression associated with 
osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet. 
2009;18:1962-75. 
71. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The 
membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat 
Med. 2004;10:182-6. 
72. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at 
the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586-99. 
73. Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, et al. 
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during 
osteosarcoma tumor progression. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2005;11:490-7. 
74. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, et al. 
Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and 
outcome in patients with osteosarcoma. Clinical cancer research : an official journal 
of the American Association for Cancer Research. 2005;11:2561-7. 
75. Sanchez-Diaz PC, Hsiao TH, Zou Y, Sugalski AJ, Heim-Hall J, Chen Y, et al. 
In silico functional analyses and discovery of survival-associated microRNA 
signatures in pediatric osteosarcoma. Oncoscience. 2014;1:599-608. 
76. Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA. MicroRNAs and Potential 
Targets in Osteosarcoma: Review. Front Pediatr. 2015;3:69. 
77. Moriarity BS, Otto GM, Rahrmann EP, Rathe SK, Wolf NK, Weg MT, et al. A 
Sleeping Beauty forward genetic screen identifies new genes and pathways driving 
osteosarcoma development and metastasis. Nat Genet. 2015;47:615-24. 
78. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving 
paradigms. Cell. 2011;147:275-92. 
79. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et 
al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after 




80. Wagenblast E, Soto M, Gutierrez-Angel S, Hartl CA, Gable AL, Maceli AR, et 
al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of 
metastasis. Nature. 2015;520:358-62. 
81. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. 
Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315-26. 
82. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-
grade osteosarcoma. Expert Opin Emerg Drugs. 2010;15:615-34. 
83. Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JA, et 
al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. 
European journal of cancer. 2009;45:2367-75. 
84. Osborne TS, Khanna C. A review of the association between osteosarcoma 
metastasis and protein translation. J Comp Pathol. 2012;146:132-42. 
85. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. 
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. 
N Engl J Med. 2004;351:781-91. 
86. Schleiermacher G, Peter M, Oberlin O, Philip T, Rubie H, Mechinaud F, et al. 
Increased risk of systemic relapses associated with bone marrow micrometastasis 
and circulating tumor cells in localized ewing tumor. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology. 2003;21:85-91. 
87. Wong IH, Chan AT, Johnson PJ. Quantitative analysis of circulating tumor 
cells in peripheral blood of osteosarcoma patients using osteoblast-specific 
messenger RNA markers: a pilot study. Clinical cancer research : an official journal of 
the American Association for Cancer Research. 2000;6:2183-8. 
88. Zhang Y, Ma Q, Liu T, Ke S, Jiang K, Wen Y, et al. Tumor self-seeding by 
circulating tumor cells in nude mouse models of human osteosarcoma and a 
preliminary study of its mechanisms. Journal of cancer research and clinical 
oncology. 2014;140:329-40. 
89. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner 
GU, et al. Osteosarcoma relapse after combined modality therapy: an analysis of 
unselected patients in the Cooperative Osteosarcoma Study Group (COSS). Journal 
of clinical oncology : official journal of the American Society of Clinical Oncology. 
2005;23:559-68. 
90. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular 
alterations as target for therapy in metastatic osteosarcoma: a review of literature. 
Clin Exp Metastasis. 2011;28:493-503. 
91. Krishnan K, Khanna C, Helman LJ. The biology of metastases in pediatric 
sarcomas. Cancer J. 2005;11:306-13. 
92. Paget S. The distribution of secondary growths in cancer of the breast. The 
Lancet. 1889;133:571-3. 
93. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark 
M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 
2015;527:329-35. 
94. Endo-Munoz L, Cai N, Cumming A, Macklin R, Merida de Long L, Topkas E, et 
al. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is 
Causally Associated with Activation of an Autocrine and Paracrine uPA Axis. PloS 
one. 2015;10:e0133592. 
95. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and 
metastasis. Cell. 2010;141:39-51. 
96. Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, et 
al. Tumor-infiltrating macrophages are associated with metastasis suppression in 
high-grade osteosarcoma: a rationale for treatment with macrophage activating 
137 
 
agents. Clinical cancer research : an official journal of the American Association for 
Cancer Research. 2011;17:2110-9. 
97. Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed 
S, et al. Macrophages inhibit human osteosarcoma cell growth after activation with 
the bacterial cell wall derivative liposomal muramyl tripeptide in combination with 
interferon-gamma. J Exp Clin Cancer Res. 2014;33:27. 
98. Odagiri H, Kadomatsu T, Endo M, Masuda T, Morioka MS, Fukuhara S, et al. 
The secreted protein ANGPTL2 promotes metastasis of osteosarcoma cells through 
integrin alpha5beta1, p38 MAPK, and matrix metalloproteinases. Sci Signal. 
2014;7:ra7. 
99. Vermeer PD, Denker J, Estin M, Moninger TO, Keshavjee S, Karp P, et al. 
MMP9 modulates tight junction integrity and cell viability in human airway epithelia. 
Am J Physiol Lung Cell Mol Physiol. 2009;296:L751-62. 
100. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of 
osteosarcoma. Nat Rev Cancer. 2014;14:722-35. 
101. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007;2:6. 
102. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, et al. 
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic 
osteosarcoma: a pediatric oncology group trial. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 2002;20:426-33. 
103. Bacci G, Ferrari S, Tienghi A, Bertoni F, Mercuri M, Longhi A, et al. A 
comparison of methods of loco-regional chemotherapy combined with systemic 
chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J 
Surg Oncol. 2001;27:98-104. 
104. Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris 
MB, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant 
chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study 
POG-8651. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology. 2003;21:1574-80. 
105. Salzer-Kuntschik M, Brand G, Delling G. [Determination of the degree of 
morphological regression following chemotherapy in malignant bone tumors]. 
Pathologe. 1983;4:135-41. 
106. Grimer RJ. Surgical options for children with osteosarcoma. The Lancet 
Oncology. 2005;6:85-92. 
107. Bertrand TE, Cruz A, Binitie O, Cheong D, Letson GD. Do Surgical Margins 
Affect Local Recurrence and Survival in Extremity, Nonmetastatic, High-grade 
Osteosarcoma? Clinical orthopaedics and related research. 2016;474:677-83. 
108. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, et al. Primary 
chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of 
the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively 
with intravenous methotrexate (high versus moderate doses) and intraarterial 
cisplatin. Cancer. 1990;65:2539-53. 
109. Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR, et al. 
International collaboration is feasible in trials for rare conditions: the EURAMOS 
experience. Cancer treatment and research. 2009;152:339-53. 
110. Medical Research Council CTU. EURAMOS I : Trial Design. 2006  [cited 2016 
4.4.2016]; Available from: http://www.ctu.mrc.ac.uk/euramos/e_i_design.asp 
111. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, et al. 
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-
randomisation treatment. Annals of oncology : official journal of the European Society 
for Medical Oncology / ESMO. 2015;26:407-14. 
138 
 
112. Jia SF, An T, Worth L, Kleinerman ES. Interferon-alpha enhances the 
sensitivity of human osteosarcoma cells to etoposide. J Interferon Cytokine Res. 
1999;19:617-24. 
113. Masuda S, Fukuma H, Beppu Y. Antitumor effect of human leukocyte 
interferon on human osteosarcoma transplanted into nude mice. European journal of 
cancer & clinical oncology. 1983;19:1521-8. 
114. Brosjo O, Bauer HC, Brostrom LA, Nilsonne U, Nilsson OS, Reinholt FP, et al. 
Influence of human alpha-interferon on four human osteosarcoma xenografts in nude 
mice. Cancer research. 1985;45:5598-602. 
115. Forster S, Triffitt JT, Bauer HC, Brosjo O, Nilsson OS, Smith R, et al. 
Interferon-inhibited human osteosarcoma xenografts induce host bone in nude mice. 
Journal of bone and mineral research : the official journal of the American Society for 
Bone and Mineral Research. 1988;3:199-202. 
116. Muller CR, Smeland S, Bauer HC, Saeter G, Strander H. Interferon-alpha as 
the only adjuvant treatment in high-grade osteosarcoma: long term results of the 
Karolinska Hospital series. Acta Oncol. 2005;44:475-80. 
117. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. 
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative 
German/Austrian study. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 1984;2:617-24. 
118. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, et al. 
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated 
Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade 
Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of 
the EURAMOS-1 Good Response Randomized Controlled Trial. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 
2015;33:2279-87. 
119. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, et al. RANKL 
maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. 
Nature. 2002;416:744-9. 
120. el-Khateeb M, Appleton TG, Gahan LR, Charles BG, Berners-Price SJ, Bolton 
AM. Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma 
ultrafiltrate studied by a combination of HPLC and NMR techniques. J Inorg Biochem. 
1999;77:13-21. 
121. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev 
Cancer. 2007;7:573-84. 
122. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev 
Cancer. 2009;9:338-50. 
123. Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, et 
al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its 
metabolites. Clin Pharmacokinet. 2001;40:41-62. 
124. Dong Q, Barsky D, Colvin ME, Melius CF, Ludeman SM, Moravek JF, et al. A 
structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 
5'-d(GAC). Proceedings of the National Academy of Sciences of the United States of 
America. 1995;92:12170-4. 
125. Hess JA, Khasawneh MK. Cancer metabolism and oxidative stress: Insights 
into carcinogenesis and chemotherapy via the non-dihydrofolate reductase effects of 
methotrexate. BBA Clin. 2015;3:152-61. 
126. Assi H, Missenard G, Terrier P, Le Pechoux C, Bonvalot S, Vanel D, et al. 
Intensive induction chemotherapy without methotrexate in adult patients with 
139 
 
localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial. Curr 
Oncol. 2010;17:23-31. 
127. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al. 
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, 
cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a 
joint study by the Italian and Scandinavian Sarcoma Groups. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 
2005;23:8845-52. 
128. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-term 
outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the 
istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 
protocol: an updated report. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2000;18:4016-27. 
129. Pratt CB, Meyer WH, Luo X, Cain AM, Kaste SC, Pappo AS, et al. Second 
malignant neoplasms occuring in survivors of osteosarcoma. Cancer. 1997;80:960-5. 
130. Kim SH, Shin KH, Seok SO, Cho YJ, Noh JK, Suh JS, et al. Secondary 
malignant neoplasms after osteosarcoma: early onset and cumulative alkylating 
agent dose dependency. Ann Surg Oncol. 2015;22:859-65. 
131. Hagleitner MM, de Bont ES, Te Loo DM. Survival trends and long-term toxicity 
in pediatric patients with osteosarcoma. Sarcoma. 2012;2012:636405. 
132. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review 
of rare acute toxicities and late effects. The Lancet Oncology. 2010;11:670-8. 
133. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, 
et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide 
and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2005;23:2004-11. 
134. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, et al. Long-term 
results of the co-operative German-Austrian-Swiss osteosarcoma study group's 
protocol COSS-86 of intensive multidrug chemotherapy and surgery for 
osteosarcoma of the limbs. Annals of oncology : official journal of the European 
Society for Medical Oncology / ESMO. 1998;9:893-9. 
135. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective 
strategies. Kidney Int. 2008;73:994-1007. 
136. Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, et 
al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. 
Cancer. 2004;100:2222-32. 
137. Klopp CT, Alford TC, Bateman J, Berry GN, Winship T. Fractionated intra-
arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary 
report. Ann Surg. 1950;132:811-32. 
138. Chuang VP, Wallace S, Benjamin RS, Jaffe N, Ayala A, Murray J, et al. The 
therapy of osteosarcoma by intraarterial cis-platinum an limb preservation. 
Cardiovasc Intervent Radiol. 1981;4:229-35. 
139. Jaffe N, Knapp J, Chuang VP, Wallace S, Ayala A, Murray J, et al. 
Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-
dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. 
Cancer. 1983;51:402-7. 
140. Mavligit GM, Benjamin R, Patt YZ, Jaffe N, Chuang V, Wallace S, et al. 




141. Stewart DJ, Benjamin RS, Zimmerman S, Caprioli RM, Wallace S, Chuang V, 
et al. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer 
Res. 1983;43:917-20. 
142. Jaffe N, Raymond AK, Ayala A, Carrasco CH, Wallace S, Robertson R, et al. 
Effect of cumulative courses of intraarterial cis-diamminedichloroplatin-II on the 
primary tumor in osteosarcoma. Cancer. 1989;63:63-7. 
143. Wilkins RM, Cullen JW, Camozzi AB, Jamroz BA, Odom L. Improved survival 
in primary nonmetastatic pediatric osteosarcoma of the extremity. Clin Orthop Relat 
Res. 2005;438:128-36. 
144. Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin KH, et al. Comparison of 
long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-
metastatic osteosarcoma of the extremity. Oncology. 2011;80:107-17. 
145. Stephens FO, Tattersall MH, Marsden W, Waugh RC, Green D, McCarthy 
SW. Regional chemotherapy with the use of cisplatin and doxorubicin as primary 
treatment for advanced sarcomas in shoulder, pelvis, and thigh. Cancer. 
1987;60:724-35. 
146. Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voute PA, 
et al. A comparison of two short intensive adjuvant chemotherapy regimens in 
operable osteosarcoma of limbs in children and young adults: the first study of the 
European Osteosarcoma Intergroup. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 1992;10:1579-91. 
147. Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck 
V, et al. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from 
the Cooperative osteosarcoma study group COSS of 925 patients]. Klinische 
Padiatrie. 1999;211:260-70. 
148. Ferrari S, Mercuri M, Picci P, Bertoni F, Brach del Prever A, Tienghi A, et al. 
Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant 
chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or 
intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic 
tumor response. Tumori. 1999;85:458-64. 
149. Hugate RR, Wilkins RM, Kelly CM, Madsen W, Hinshaw I, Camozzi AB. 
Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults. Clin 
Orthop Relat Res. 2008;466:1292-301. 
150. Tunn PU, Schmidt-Peter P, Pomraenke D, Hohenberger P. Osteosarcoma in 
children: long-term functional analysis. Clinical orthopaedics and related research. 
2004:212-7. 
151. Winkler K, Bielack S, Delling G, Salzer-Kuntschik M, Kotz R, Greenshaw C, et 
al. Effect of intraarterial versus intravenous cisplatin in addition to systemic 
doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in 
osteosarcoma (study COSS-86). Cancer. 1990;66:1703-10. 
152. Rasch CR, Hauptmann M, Schornagel J, Wijers O, Buter J, Gregor T, et al. 
Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: 
Results of a randomized phase 3 trial. Cancer. 2010;116:2159-65. 
153. Suzuki S, Yasunaga H, Matsui H, Fushimi K, Saito Y, Yamasoba T. Cerebral 
infarction after intraarterial and intravenous chemoradiotherapy for head and neck 
cancer: A retrospective analysis using a Japanese inpatient database. Head & neck. 
2016. 
154. Imbesi F, Marchioni E, Benericetti E, Zappoli F, Galli A, Corato M, et al. A 
randomized phase III study: comparison between intravenous and intraarterial ACNU 




155. Stewart DJ, Grahovac Z, Hugenholtz H, DaSilva V, Richard MT, Benoit B, et 
al. Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide 
combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and 
mannitol in the treatment of primary and metastatic brain tumors. J Neurooncol. 
1993;17:71-9. 
156. Rodriguez CO, Jr. Using canine osteosarcoma as a model to assess efficacy 
of novel therapies: can old dogs teach us new tricks? Adv Exp Med Biol. 
2014;804:237-56. 
157. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, et al. Canine 
tumor cross-species genomics uncovers targets linked to osteosarcoma progression. 
BMC Genomics. 2009;10:625. 
158. Powers BE, Withrow SJ, Thrall DE, Straw RC, LaRue SM, Page RL, et al. 
Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. 
Cancer. 1991;67:126-34. 
159. Harker G, Stephens F. A report on the comparative response of sheep 
epidermal squamous-cell carcinoma to intraarterial versus intravenous Cisplatin 
infusion. Int J Oncol. 1995;7:365-70. 
160. Yamada K, Ushio Y, Hayakawa T, Arita N, Huang TY, Nagatani M, et al. 
Distribution of radiolabeled 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-
chloroethyl)-3-nitros ourea hydrochloride in rat brain tumor: intraarterial versus 
intravenous administration. Cancer research. 1987;47:2123-8. 
161. Takeda N, Diksic M, Yamamoto YL. The sequential changes in DNA 
synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine 
receptor density in C6 brain tumors after chemotherapy to predict the response of 
tumors to chemotherapy. Cancer. 1996;77:1167-79. 
162. Schuster JM, Friedman HS, Archer GE, Fuchs HE, McLendon RE, Colvin OM, 
et al. Intraarterial therapy of human glioma xenografts in athymic rats using 4-
hydroperoxycyclophosphamide. Cancer research. 1993;53:2338-43. 
163. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer 
research: a historical perspective. Pharmacol Ther. 1994;64:529-64. 
164. Modiano JF, Bellgrau D, Cutter GR, Lana SE, Ehrhart NP, Ehrhart E, et al. 
Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene 
therapy improves survival of dogs with spontaneous bone cancer. Mol Ther. 
2012;20:2234-43. 
165. Lascelles BD, Dernell WS, Correa MT, Lafferty M, Devitt CM, Kuntz CA, et al. 
Improved survival associated with postoperative wound infection in dogs treated with 
limb-salvage surgery for osteosarcoma. Ann Surg Oncol. 2005;12:1073-83. 
166. EMA. European public assessment reports. 2009 01/10/2013 [cited 2016 
9/5/2016]; Available from: www.ema.europa.eu 
167. Ando K, Mori K, Corradini N, Redini F, Heymann D. Mifamurtide for the 
treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011;12:285-
92. 
168. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II 
study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and 
monocyte activation following administration. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 1992;10:1310-6. 
169. MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, 
et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-




170. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et 
al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves 
overall survival--a report from the Children's Oncology Group. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 2008;26:633-
8. 
171. Liu T, Fang XC, Ding Z, Sun ZG, Sun LM, Wang YL. Pre-operative 
lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering 
from osteosarcoma. FEBS Open Bio. 2015;5:682-7. 
172. Fritzsching B, Fellenberg J, Moskovszky L, Sapi Z, Krenacs T, Machado I, et 
al. CD8/FOXP3-ratio in osteosarcoma microenvironment separates survivors from 
non-survivors: a multicenter validated retrospective study. Oncoimmunology. 
2015;4:e990800. 
173. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An 
endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the 
National Academy of Sciences of the United States of America. 1975;72:3666-70. 
174. Croft M, Duan W, Choi H, Eun SY, Madireddi S, Mehta A. TNF superfamily in 
inflammatory disease: translating basic insights. Trends Immunol. 2012;33:144-52. 
175. Haraoui B, Bykerk V. Etanercept in the treatment of rheumatoid arthritis. Ther 
Clin Risk Manag. 2007;3:99-105. 
176. Peters CP, Eshuis EJ, Toxopeus FM, Hellemons ME, Jansen JM, D'Haens 
GR, et al. Adalimumab for Crohn's disease: long-term sustained benefit in a 
population-based cohort of 438 patients. J Crohns Colitis. 2014;8:866-75. 
177. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, 
et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 
2004;350:876-85. 
178. Zelova H, Hosek J. TNF-alpha signalling and inflammation: interactions 
between old acquaintances. Inflamm Res. 2013;62:641-51. 
179. Bradley JR. TNF-mediated inflammatory disease. The Journal of pathology. 
2008;214:149-60. 
180. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. 
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. 
Nature. 1997;385:729-33. 
181. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, et al. The 
transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 
kDa tumor necrosis factor receptor. Cell. 1995;83:793-802. 
182. Mark KS, Trickler WJ, Miller DW. Tumor necrosis factor-alpha induces 
cyclooxygenase-2 expression and prostaglandin release in brain microvessel 
endothelial cells. The Journal of pharmacology and experimental therapeutics. 
2001;297:1051-8. 
183. Goldblum SE, Sun WL. Tumor necrosis factor-alpha augments pulmonary 
arterial transendothelial albumin flux in vitro. Am J Physiol. 1990;258:L57-67. 
184. Chandrasekharan UM, Siemionow M, Unsal M, Yang L, Poptic E, Bohn J, et 
al. Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-
induced leukocyte-endothelial interaction in vivo. Blood. 2007;109:1938-44. 
185. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 
2001;357:539-45. 
186. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol. 
2009;201:309-20. 
187. Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, et al. 




188. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a 
tumour promoter. European journal of cancer. 2006;42:745-50. 
189. Regenass U, Muller M, Curschellas E, Matter A. Anti-tumor effects of tumor 
necrosis factor in combination with chemotherapeutic agents. International journal of 
cancer Journal international du cancer. 1987;39:266-73. 
190. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for 
the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor 
vasculature induced by TNF and IFN-gamma. Nature medicine. 1998;4:408-14. 
191. Havell EA, Fiers W, North RJ. The antitumor function of tumor necrosis factor 
(TNF), I. Therapeutic action of TNF against an established murine sarcoma is 
indirect, immunologically dependent, and limited by severe toxicity. J Exp Med. 
1988;167:1067-85. 
192. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. 
Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, 
interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proceedings 
of the National Academy of Sciences of the United States of America. 1993;90:2774-
8. 
193. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and 
therapeutic target. Annu Rev Med. 1994;45:491-503. 
194. Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, 
Eggermont AM. Outcome and prognostic factor analysis of 217 consecutive isolated 
limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening 
soft tissue sarcoma. Cancer. 2006;106:1776-84. 
195. Deroose JP, Eggermont AM, van Geel AN, de Wilt JH, Burger JW, Verhoef C. 
20 years experience of TNF-based isolated limb perfusion for in-transit melanoma 
metastases: TNF dose matters. Ann Surg Oncol. 2012;19:627-35. 
196. Hernandez J, Cooper J, Babel N, Morton C, Rosemurgy AS. TNFalpha gene 
delivery therapy for solid tumors. Expert Opin Biol Ther. 2010;10:993-9. 
197. Hayashi A, Hayashi H, Chiba T, Sasayama S, Onozaki K. N-acetylneuraminic 
acid coupled human recombinant TNFalpha exhibits enhanced anti-tumor activity 
against Meth-A fibrosarcoma and reduced toxicity. Cancer Immunol Immunother. 
2007;56:555-62. 
198. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, et al. 
Selective targeted delivery of TNFalpha to tumor blood vessels. Blood. 
2003;102:4384-92. 
199. Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, 
Hoekstra HJ, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha 
in combination with interferon-gamma and melphalan for nonresectable extremity soft 
tissue sarcomas: a multicenter trial. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 1996;14:2653-65. 
200. Deroose JP, Grunhagen DJ, de Wilt JH, Eggermont AM, Verhoef C. Treatment 
modifications in tumour necrosis factor-alpha (TNF)-based isolated limb perfusion in 
patients with advanced extremity soft tissue sarcomas. European journal of cancer. 
2015;51:367-73. 
201. Van Ginkel RJ, Van Berlo CL, Baas PC, Koops HS, Stuling RV, Elstrodt J, et 
al. Hyperthermic Isolated Limb Perfusion with TNF alpha and Cisplatin in the 
Treatment of Osteosarcoma of the Extremities: A Feasibility Study in Healthy Dogs. 
Sarcoma. 1999;3:89-94. 
202. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human 
TNF in human cancer therapy. Cancer Immun. 2006;6:6. 
144 
 
203. Bickels J, Manusama ER, Gutman M, Eggermont AM, Kollender Y, Abu-Abid 
S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for 
unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol. 1999;25:509-
14. 
204. Kato H, Wakabayashi H, Naito Y, Kato S, Nakagawa T, Matsumine A, et al. 
Anti-tumor necrosis factor therapy inhibits lung metastasis in an osteosarcoma cell 
line. Oncology. 2015;88:139-46. 
205. Harimaya K, Tanaka K, Matsumoto Y, Sato H, Matsuda S, Iwamoto Y. 
Antioxidants inhibit TNFalpha-induced motility and invasion of human osteosarcoma 
cells: possible involvement of NFkappaB activation. Clinical & experimental 
metastasis. 2000;18:121-9. 
206. Mori T, Sato Y, Miyamoto K, Kobayashi T, Shimizu T, Kanagawa H, et al. 
TNFalpha promotes osteosarcoma progression by maintaining tumor cells in an 
undifferentiated state. Oncogene. 2014;33:4236-41. 
207. van Etten B, de Vries MR, van IMG, Lans TE, Guetens G, Ambagtsheer G, et 
al. Degree of tumour vascularity correlates with drug accumulation and tumour 
response upon TNF-alpha-based isolated hepatic perfusion. British journal of cancer. 
2003;88:314-9. 
208. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten 
Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-
alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour 
effects. British journal of cancer. 2000;82:973-80. 
209. Yu Z, Geng J, Zhang M, Zhou Y, Fan Q, Chen J. Treatment of osteosarcoma 
with microwave thermal ablation to induce immunogenic cell death. Oncotarget. 
2014;5:6526-39. 
210. Gasparri A, Moro M, Curnis F, Sacchi A, Pagano S, Veglia F, et al. Tumor 
pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis 
factor alpha in mouse models. Cancer research. 1999;59:2917-23. 
211. Palladino MA, Jr., Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, 
Deleo AB, et al. Characterization of the antitumor activities of human tumor necrosis 
factor-alpha and the comparison with other cytokines: induction of tumor-specific 
immunity. J Immunol. 1987;138:4023-32. 
212. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by 
tumor necrosis factor. J Exp Med. 1986;163:740-5. 
213. Hemmerle T, Probst P, Giovannoni L, Green AJ, Meyer T, Neri D. The 
antibody-based targeted delivery of TNF in combination with doxorubicin eradicates 
sarcomas in mice and confers protective immunity. British journal of cancer. 
2013;109:1206-13. 
214. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of 
tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted 
delivery to aminopeptidase N (CD13). Nature biotechnology. 2000;18:1185-90. 
215. Lu L, Li ZJ, Li LF, Wu WK, Shen J, Zhang L, et al. Vascular-targeted 
TNFalpha improves tumor blood vessel function and enhances antitumor immunity 
and chemotherapy in colorectal cancer. J Control Release. 2015;210:134-46. 
216. Johansson A, Hamzah J, Payne CJ, Ganss R. Tumor-targeted TNFalpha 
stabilizes tumor vessels and enhances active immunotherapy. Proceedings of the 
National Academy of Sciences of the United States of America. 2012;109:7841-6. 
217. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A. 
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor 
vasculature-targeted tumor necrosis factor-alpha. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 2006;12:175-82. 
145 
 
218. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, et al. Localization 
and density of immune cells in the invasive margin of human colorectal cancer liver 
metastases are prognostic for response to chemotherapy. Cancer research. 
2011;71:5670-7. 
219. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-
associated lymphocytes as an independent predictor of response to neoadjuvant 
chemotherapy in breast cancer. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2010;28:105-13. 
220. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. 
Leukocyte complexity predicts breast cancer survival and functionally regulates 
response to chemotherapy. Cancer Discov. 2011;1:54-67. 
221. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, 
et al. Lymphopenia as a prognostic factor for overall survival in advanced 
carcinomas, sarcomas, and lymphomas. Cancer research. 2009;69:5383-91. 
222. Tanaka H, Matsushima H, Mizumoto N, Takashima A. Classification of 
chemotherapeutic agents based on their differential in vitro effects on dendritic cells. 
Cancer research. 2009;69:6978-86. 
223. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et 
al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J 
Exp Med. 2005;202:1691-701. 
224. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like 
receptor 4-dependent contribution of the immune system to anticancer chemotherapy 
and radiotherapy. Nature medicine. 2007;13:1050-9. 
225. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, et al. 
Restoration of the immunogenicity of cisplatin-induced cancer cell death by 
endoplasmic reticulum stress. Oncogene. 2011;30:1147-58. 
226. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, et al. Cardiac 
glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl 
Med. 2012;4:143ra99. 
227. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. 
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature 
medicine. 2007;13:54-61. 
228. Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD, et 
al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with 
autologous tumor cells experiencing immunogenic death. Cancer research. 
2010;70:9062-72. 
229. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in 
tumors by vascular targeting and barrier alteration. J Clin Invest. 2002;110:475-82. 
230. Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, 
Seynhaeve AL, et al. Tumor necrosis factor-alpha augmented tumor response in 
B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) 
correlates with altered Doxil pharmacokinetics. International journal of cancer Journal 
international du cancer. 2004;109:442-8. 
231. Manara M, Sinigaglia L. Bone and TNF in rheumatoid arthritis: clinical 
implications. RMD Open. 2015;1:e000065. 
232. Osta B, Benedetti G, Miossec P. Classical and Paradoxical Effects of TNF-
alpha on Bone Homeostasis. Front Immunol. 2014;5:48. 
233. Sawicka M, Pawlikowski J, Wilson S, Ferdinando D, Wu H, Adams PD, et al. 
The specificity and patterns of staining in human cells and tissues of p16INK4a 
antibodies demonstrate variant antigen binding. PloS one. 2013;8:e53313. 
146 
 
234. Suzuki K, Bose P, Leong-Quong RY, Fujita DJ, Riabowol K. REAP: A two 
minute cell fractionation method. BMC Res Notes. 2010;3:294. 
235. Park YB, Park MJ, Kimura K, Shimizu K, Lee SH, Yokota J. Alterations in the 
INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. 
Cancer Genet Cytogenet. 2002;133:105-11. 
236. Evangelou K, Bramis J, Peros I, Zacharatos P, Dasiou-Plakida D, 
Kalogeropoulos N, et al. Electron microscopy evidence that cytoplasmic localization 
of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is 
specific and not an artifact. A study in non-small cell lung carcinomas. Biotech 
Histochem. 2004;79:5-10. 
237. Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart ME, Castellvi J, 
et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with 
senescence and high-grade tumors. Oncogene. 2011;30:2087-97. 
238. Nilsson K, Landberg G. Subcellular localization, modification and protein 
complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor 
cells. International journal of cancer Journal international du cancer. 2006;118:1120-
5. 
239. Shen WW, Wu J, Cai L, Liu BY, Gao Y, Chen GQ, et al. Expression of anion 
exchanger 1 sequestrates p16 in the cytoplasm in gastric and colonic 
adenocarcinoma. Neoplasia. 2007;9:812-9. 
240. Chen YW, Chu HC, Ze-Shiang L, Shiah WJ, Chou CP, Klimstra DS, et al. p16 
Stimulates CDC42-dependent migration of hepatocellular carcinoma cells. PloS one. 
2013;8:e69389. 
241. Goto T, Takano M, Hirata J, Kohno T, Ohtsuka S, Fujiwara K, et al. p16INK4a 
expression in cytology of ascites and response to chemotherapy in advanced ovarian 
cancer. International journal of cancer Journal international du cancer. 2009;125:339-
44. 
242. Robl B, Pauli C, Botter SM, Bode-Lesniewska B, Fuchs B. Prognostic value of 
tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy. 
BMC Cancer. 2015;15:379. 
243. Kinoshita Y, Kalir T, Rahaman J, Dottino P, Kohtz DS. Alterations in nuclear 
pore architecture allow cancer cell entry into or exit from drug-resistant dormancy. 
Am J Pathol. 2012;180:375-89. 
244. Widakowich C, de Castro G, Jr., de Azambuja E, Dinh P, Awada A. Review: 
side effects of approved molecular targeted therapies in solid cancers. Oncologist. 
2007;12:1443-55. 
245. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of 
conventional and targeted anticancer therapies: reinstating immunosurveillance. 
Immunity. 2013;39:74-88. 
246. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et 
al. Protein expression and functional difference of membrane-bound and soluble 
receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic 







10 Curriculum Vitae 
Name   ROBL Bernhard 
Date of Birth 15.10.1987 
Place of origin Vienna, Austria 
E-mail  Bernhard.robl@gmail.com 
 
Education 
Apr 2012 - Dec 2016 PhD Study in the Laboratory for Orthopedic Research, 
Balgrist University Hospital, Zurich, Switzerland within the 
“Cancer Biology” PhD Program of Life Science Zurich 
Graduate School, Faculty of Science, University of Zurich  
Oct 2009 - Nov 2011 MSc in Molecular Bioengineering, Technische Universität 
Dresden, Germany  
  Thesis Title: “Effects of flue gases on photosynthetic 
enzymes of microalgae” 
Sep 2006 - Jun 2009 BSc in medical and pharmaceutical Biotechnology, IMC 
FH Krems - University of applied Sciences, Austria 






Robl B, Botter SM, Boro A, Meier D, Neri D, Fuchs B. Evaluation of F8-TNF-α in a model of 
early stage and progressed murine osteosarcoma. Work in progress. 
 
Robl B, Botter SM, Pellegrini G, Neklyudova O, Fuchs B. Evaluation of intraarterial and 
intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an 
orthotopic xenograft mouse model. J Exp Clin Cancer Res. 2016 Jul 16;35(1):113. 
 
Neklyudova O, Arlt MJE, Brennecke P, Thelen M, Gvozdenovic A, Kuzmanov A, Robl B, 
Botter S, Born W, Fuchs B. Altered CXCL12 expression reveals a dual role of CXCR4 in 
osteosarcoma primary tumor growth and metastasis. J Cancer Res Clin Oncol. 2016, 
142(8):1739. 
 
Boro A, Arlt MJ, Lengnick H, Robl B, Husmann M, Bertz J, Born W, Fuchs B. Prognostic 
value and in vitro biological relevance of Neuropilin 1 and Neuropilin 2 in osteosarcoma. Am 
J Transl Res. 2015, 7(3):640. 
 
Robl B, Pauli C, Botter SM, Bode-Lesniewska B, Fuchs B. Prognostic value of tumor 
suppressors in osteosarcoma before and after neoadjuvant chemotherapy. BMC Cancer. 
2015, 15:379. 
 
Jentzsch T, Robl B, Husmann M, Bode-Lesniewska B, Fuchs B. Expression of MSH2 and 
MSH6 on a tissue microarray in patients with osteosarcoma. Anticancer Res. 2014, 
34(12):6961. 
 
Ram Kumar RM, Betz MM, Robl B, Born W, Fuchs B. ∆Np63α enhances the oncogenic 
phenotype of osteosarcoma cells by inducing the expression of GLI2. BMC Cancer.  2014, 
14:559. 
 
Jentzsch T, Robl B, Husmann M, Bode-Lesniewska B, Fuchs B. Worse prognosis of 
osteosarcoma patients expressing IGF-1 on a tissue microarray. Anticancer Res. 2014, 
34(8):3881. 
 
McHedlishvili L, Mazurov V, Grassme KS, Goehler K, Robl B, Tazaki A, Roensch K, 
Duemmler A, Tanaka EM. Reconstitution of the central and peripheral nervous system during 




I would like to express my gratitude to Prof. Dr. Dr. Bruno Fuchs for providing me 
with the opportunity of conducting my doctoral work in his laboratory, for his support, 
advice, demonstrations and trust in my work.  
I am thankful to my thesis director Prof. Dr. Ian Frew for kindly and optimistically 
guiding me through my doctoral studies as well as for being in my thesis committee, 
for his administrative support and for his scientific suggestions. 
Furthermore, I would also like to show my respect and appreciation for my thesis 
committee members Prof. Dr. Lubor Borsig and Prof. Dr. Dario Neri, especially for 
their scientific expertise, their inspiring contributions as well as their bureaucratic 
support and supplies. 
I am grateful to my supervisor Dr. Sander Botter for his supervision, availability and 
constant help throughout my PhD. Most of all, I would like to thank him for his 
patience during frequent discussions. 
Special thanks go to Dr. Ana Gvozdenovic, Dr. Aleksandar Boro, Dr. Matthias Arlt 
and Dr. Adam Sabile for their generous help and advices throughout my PhD.  They 
taught me a lot about solving biological problems and provided me technical help. 
Many thanks also to all my current lab colleagues for their help, cheerfulness and the 
friendly atmosphere in the lab. Thank you, Daniela, Olga, Joaquin and Alekhya, for 
your help, for being friends and for cheering me up when times were tough or 
celebrating with me when times were good. 
I would also like to thank my external collaborators, especially Dr. Giovanni 
Pellegrini for his profound knowledge in veterinary pathology, patience and for letting 
150 
 
me be his first customer. Also Dr. Chantal Pauli always had time for me including the 
weekends when I needed to discuss important issues about human sarcoma biology 
and Philipp Probst, who always provided me with endless supplies of antibodies 
and technical advice to successfully complete my work. 
Without, external evaluation of doctoral issues, this work would not have been 
possible. Due to their objective opinions, friendly advices and great support during 
my spare time, I would like to thank Laura, Tamara, Franziska, Sabine, Vinod, 
Johannes, Julian and Martin. 
My wholehearted gratitude belongs to my parents Roswitha and Gerhard for their 
love, great support across borders and for always supporting my work and ventures. 
Special thanks also to my only sister Claudia, her support, help in solving Austrian 
issues and the good times we have spent together. 
Last but not least, I am expressing my deepest gratitude to my girlfriend and fiancé 
Lisa for exciting and fun times, for always being by my side and for sharing her life 
with me. I would like to specifically thank her for supporting me during stressful times, 
and motivating me in a way, that everything seemed possible.  
 
Thank you so much. 
